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Hormone replacement therapy (HRT) and the combined oral contraceptive pill (COCP) are both 
commonly used for oestrogen replacement in premature ovarian failure but there is a lack of 
evidence of their effects.  We compared the effects of combined HRT (Nuvelle) and the COCP 
(Microgynon 30) in 30 women with premature ovarian failure in a two year open-label 
randomised trial.  29 women who declined to take treatment were also followed using the same 
protocol.  36 women (61%) completed the trial (15 in the no treatment group; 12 in the HRT 
group; 9 in the COCP group).  In comparison with the COCP, treatment with HRT increased 
bone mineral density at the lumbar spine at 2 years, which was the primary outcome measure 
(+0.038 g/cm2; 95% CI 0.002 to 0.073; p 0.040; linear regression using adjustment for baseline 
values).  Bone turnover markers (P1NP and CTX) showed similar reductions in the two 
treatment groups.  There were trends in favour of HRT in lipid profile, high sensitivity C-reactive 
protein, blood pressure and sexual function.  The HRT group had a significantly greater 
reduction in menopausal symptoms at 24 months.  Improvements in most symptom scores took 
longer in the COCP group.  
In the no treatment group, bone density dropped at all sites over the course of the trial.  The no 
treatment group also performed poorly in comparison with the treatment groups in bone 
turnover, depression score and menopausal symptoms score.  
These findings will have important implications for counselling young women with premature 
ovarian failure on their choice of oestrogen replacement.  We have shown that in many respects 
HRT performed superiorly to the COCP.  However, further research is required to confirm these 
effects.  The results from the no treatment group will enable women who choose to decline 
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Chapter 1 Introduction and Aims of Thesis 
1.1 Introduction 
Premature ovarian failure (POF), sometimes called early menopause, is a devastating condition.  
It is defined as a loss of ovarian function before the age of 45 (British Menopause Society 
definition) (1).  POF is not uncommon, spontaneously affecting 1% of women under the age of 
40 and 5% before 45 (2).  POF is not the same as the normal menopause (which occurs at an 
average age of 52 in the UK) because in POF intermittent ovarian function may continue in an 
unpredictable fashion for many years.  This has been demonstrated by ultrasound studies 
following the growth of ovarian follicles and the observation of spontaneous pregnancies 
occurring after the diagnosis of POF in 5-10% of women (3, 4). 
The diagnosis of POF carries enormous impact for a young woman from both a physical and 
psychological perspective.  It will affect almost every aspect of her life, from causing menopausal 
symptoms to influencing long term health risks, as well as meaning that there is little chance of 
conceiving a pregnancy naturally.   
It is worth noting that some countries use the cut-off of 40 rather than 45 to define POF.  
However, a woman who experiences POF at the age of 44 has 8 extra years of oestrogen 
deficiency compared with a woman who has her menopause at 52.  She is exposed to all the 
risks of early oestrogen deficiency, including bone loss.  We therefore use the British 
Menopause Society’s definition both in clinical practice and for this research project.    
In POF the ovaries stop producing normal levels of oestrogen.  The resulting low oestrogen level 
has many consequences.  Arguably the most important is its effect on the bone, where a lack of 
oestrogen causes early bone loss which can ultimately lead to osteoporosis.  Osteoporosis 
increases the likelihood of bone fractures, which can lead to considerable morbidity and 
decreased life expectancy – for example data suggest a death rate of 20-30% from all causes 
within one year following a fractured neck of femur (5).  A recent service evaluation of women 
seen in the POF clinic at GSTT (Guy’s and St Thomas’ NHS Foundation Trust) revealed that 
loss of bone density is the main concern for over 70%.  Previous trials investigating bone density 
in POF have been observational and retrospective.  Several studies have shown that women 
with POF have reduced bone density, and one retrospective study has shown that they have a 
lifelong increased risk of fractures (6-10).  To date, there have been no prospective studies in 
spontaneous POF investigating the quantitative effects on bone density of different treatments or 
no treatment.   
Another long-term consequence of POF is increased cardiovascular risk (11, 12)  This may in 
part be due to a change in lipid profile seen in POF (13).  Osteoporosis and cardiovascular 
events can seriously affect life expectancy and quality of life.  Cardiovascular disease is the 
leading cause of mortality in women.  It is likely that the management of POF at the time of 
diagnosis will affect the development and impact of osteoporosis and cardiovascular disease in 




Studies also indicate that women with POF have high levels of depression and sexual 
dysfunction (14, 15).  However, no previous studies have assessed the full range of symptoms 
that may be experienced in POF, or the effects of different treatments or no treatment on these.   
Oestrogen replacement is recommended for women with POF, either in the form of hormone 
replacement therapy or the combined oral contraceptive pill, in order to alleviate menopausal 
symptoms and protect against the long term health sequelae of bone loss and increased 
cardiovascular risk.  However, the most suitable form of oestrogen replacement is unknown and 
management is not currently evidence-based.  This is acknowledged in most reviews on the 
subject.(1, 16, 17)  In 2004, the RCOG Menopause and Hormone Replacement study group 
advised that research is recommended ‘to develop and assess treatment strategies in women 
with premature menopause’.  Very few studies have as yet been carried out.  Hormone 
replacement therapy or the combined oral contraceptive pill are the two broad choices but there 
is very little evidence-based information on their relative advantages and disadvantages in this 
context.  This makes it extremely difficult to provide accurate advice to affected women.   
HRT is considered to be more 'physiological' but some young women dislike taking a 
preparation which they associate with older women.  Some women may also find that a 
standard dose of HRT is not adequate to control their symptoms.  The COCP contains synthetic 
oestrogen at a higher dose but with a 'pill free' week.  It may be the preferred choice for some 
young women as it is a medication they are familiar with, it does not carry HRT’s association 
with older women, and it is generally more ’peer-friendly’.  Women with POF face many years of 
oestrogen replacement and deserve to know more about the relative advantages and 
disadvantages of different treatments, particularly in relation to long term health outcomes such 
as preventing bone loss and minimising cardiovascular risk.   
There are also a significant proportion of women who decline treatment as they feel it is 
'unnatural' or are concerned about the safety or side effects.  There have been no prospective 
studies in spontaneous POF investigating the effects of different treatments or no treatment.  In 
a patient-centred approach to health care, these data are vital to enable affected women to 
make treatment choices.   
This study assesses the effects of hormone replacement therapy, the combined oral 
contraceptive pill and no treatment on bone density and turnover, cardiovascular risk, ovarian 
function, menopausal symptoms, sexual function, depression and quality of life in women with 
premature ovarian failure.  The results will help women make informed decisions about their 
method of treatment.   
The term ‘premature ovarian failure’ is being succeeded by the term ‘premature ovarian 
insufficiency’ or even ‘primary premature ovarian insufficiency’.  These new terms are more 
accurate, in that ovarian function does not necessarily fail completely and permanently, and 
they are considered to be more sensitive for affected women.  However, the term ‘premature 
ovarian failure’ has been used throughout this thesis because the trial was named and started 




1.2 Aims of Thesis 
The aim of this study was to compare the effects of a combined hormone replacement therapy 
(Nuvelle; oestradiol 2mg daily, plus levonorgestrel 75mcg for 12 days a month) with a combined 
oral contraceptive pill (Microgynon 30; ethinyloestradiol 30mcg and levonorgestrel 150mcg 
taken for 3 weeks then with a one week break) on bone density and other parameters in women 
with premature ovarian failure, and to observe the same outcomes in women who chose not to 
take any treatment.   
We hypothesised that in the two treatment groups (HRT and the COCP) bone density would be 
maintained and that women in the no treatment group would experience a decrease in bone 
density at the normal post-menopausal rate (2-3% per year initially and approximately 1% per 
year subsequently).  However, due to the intermittent nature of POF we also considered the 
possibility that in some untreated women bone loss would be less severe.   
The primary outcome was a change in lumbar spine bone mineral density (assessed by dual 
energy X-ray absorptiometry; DXA) at 24 months.   
Secondary outcomes were changes in: 
- Total hip and femoral neck bone mineral density  
o assessed by DXA 
- Cardiovascular markers  
o assessed by total cholesterol, LDL cholesterol, triglycerides, high sensitivity C-
reactive protein 
- Ovarian function  
o assessed by trans-vaginal ultrasound for antral follicle count and ovarian volume 
and serum anti-Mullerian hormone and inhibin B 
- Menopausal symptoms  
o assessed by Greene Climacteric Scale and Menopause Symptoms Treatment 
Satisfaction Questionnaire 
- Sexual Function  
o assessed by Brief Profile of Female Sexual Function 
- Depression  
o assessed by Patient Health Questionnaire-9 
- Quality of Life  





Chapter 2 Literature Review 
2.1 Pathophysiology of premature ovarian failure (POF) 
Premature ovarian failure (POF) is defined as a loss of ovarian function before the age of 45 
(British Menopause Society) (1).  POF can be secondary to chemotherapy, radiotherapy, pelvic 
surgery, infection or removal of the ovaries, or it can happen spontaneously.  The prevalence of 
spontaneous POF before the age of forty is estimated at 1% and before forty-five at 5% (2).  In 
the majority of cases of spontaneous POF the cause is unknown (idiopathic POF).  Recognised 
causes include autoimmune disease, Fragile X premutation and other genetic disorders (table 
1).   
The mechanism of idiopathic spontaneous POF is unknown.  A reduced initial number of 
oocytes, accelerated oocyte atresia and follicular dysfunction have been suggested.  POF is 
different from the ‘normal’ menopause because ovarian function may be intermittent and 
unpredictable.  Pregnancy may occur, sometimes many years after diagnosis (3), and studies 
monitoring ovarian activity have shown that over 80% have ovarian follicular activity and almost 
50% ovulate (4).   
Causes of spontaneous POF Causes of secondary POF 
No cause found (idiopathic) Bilateral oophorectomy 
Autoimmune disease Chemotherapy 
Fragile X premutation Radiotherapy 
Other genetic causes – e.g. Turner’s 
syndrome, Down’s syndrome, rare mutations 
such as FSH receptor polymorphism and 
inhibin B mutation 
Interruption of ovarian blood supply due to 
pelvic surgery or uterine artery embolisation 
Enzyme deficiencies – e.g. galactosaemia,  Infections – mumps, tuberculosis, HIV 
Table 1 Causes of spontaneous and secondary premature ovarian failure 
 
2.1.1 Mechanism of normal menopause 
The median age of menopause in the UK is 52 (18). The ovaries have a finite number of 
oocytes and a certain number undergo atresia each month, starting antenatally.  The rate of 
decline of ovarian follicles in humans is more complicated than the simple exponential decline 
seen for example in rats.  Using histological data from several studies estimating ovarian follicle 




change of number of follicles is proportional to the number remaining.  This means that there is 
little change in the rate of exponential decline until the late 30s, when the number of follicles is 
approximately 25,000, and the rate of decline increases sharply (19).  This model was found to 
correspond very closely with the distribution of age at menopause, with the timing of 
menopause corresponding with a median pool of 1100 follicles (19).  Another model using new 
histological data also estimated that at the menopause about 1000 follicles remain (20). 
As the number of follicles approaches this threshold, the ovaries become less responsive to 
follicle stimulating hormone (FSH) produced by the pituitary, less follicles develop and oestradiol 
levels decrease.  The loss of negative feedback of oestradiol and other ovarian hormones 
causes serum FSH to rise.  In the early peri-menopause the remaining follicles occasionally 
respond to the high FSH levels and start to develop and produce oestradiol, causing significant 
fluctuations in serum oestradiol and FSH.  This stops as the follicles become more depleted and 
eventually the FSH remains high, the ovaries become completely inactive and serum oestradiol 
becomes very low.   
2.1.2 Spontaneous premature ovarian failure 
A cause for spontaneous POF is identified in approximately 35%, although the sampling bias in 
studies of women attending clinics could render this an over-estimate.  A genetic aetiology is 
reported in approximately 5% (21) and autoimmune in up to 30% (22), although this is likely to 
depend heavily on the clinic referral base.  At least 65% have no identifiable cause and it is likely 
that this figure is much higher for the general POF population.  At Guy’s and St Thomas’ 85% 
with spontaneous POF had no cause identified from routine clinic investigations (23). The largest 
study investigating causes of POF reviewed 357 women aged under 40 years at diagnosis who 
were referred to the national POF centre in France (24).  14% were found to have signs of 
clinical or biochemical autoimmunity and 7% had a genetic cause.  Of note, 24% of the women 
in this study presented with primary amenorrhoea; unfortunately the authors do not provide 
separate data for this group but report that in the majority there was no identifiable aetiology.   
2.1.2.1 Genetic causes 
Many cases of spontaneous POF appear to be inherited, although estimates have varied widely, 
from approximately 4 to 31% (25).  Whilst causative mutations in some genes have been 
identified (26), it is not practical to test for these routinely and it is likely that there are many more 
which are as yet undiscovered.  The two genetic causes of POF which can be readily tested for 
are the FMR1 (fragile X) premutation and chromosomal disorders, such as Turner syndrome, 
which can be assessed on karyotype.   
2.1.2.1.1 Fragile X premutation 
The FMR1 (fragile X) premutation, defined as 55 to 200 CGG repeats in the FMR1 gene, is 
responsible for approximately 4-5% of cases of POF overall (21, 27).  In women with a positive 




with no family history (27).  It is important to identify those carrying the FMR1 premutation for 
several reasons.  In the event of spontaneous conception these individuals are at risk of having 
a child with fragile X syndrome; 3 such cases have been reported (28).  For medico-legal 
reasons it is important to inform women of this possibility.  Other issues to consider are 
disclosure and offering testing to other family members and that the premutation can 
occasionally be associated with a neurodegenerative disorder (29).  The premutation has been 
estimated to occur in between 1 in 113 to 1 in 259 women in the general population (30-32).  
Women with the FMR1 premutation have a risk of approximately 15% of developing POF (33).   
The FMR1 gene codes for a RNA binding protein called fragile X mental retardation protein 
(FMRP).  In the full mutation, no FMRP is produced.  In the premutation, there is a normal 
amount of FMRP but excess messenger RNA production, which may be the cause of ovarian 
damage.  However, the exact mechanism behind this is unknown. 
2.1.2.1.2 X chromosome disorders 
The X chromosome contains genes which are vital for normal ovarian development and 
function.  Turner syndrome, characterised by the absence of all or part of the second X 
chromosome, affects approximately 1 in 2500 live female babies (34).  The number of 
primordial follicles in utero is reduced and these then undergo premature apoptosis, resulting in 
ovarian dysgenesis and streak ovaries.  The mechanisms behind this are unknown.  Most girls 
with a 45 XO karyotype do not enter puberty but 40% of those with 45X/46XX mosaicism do; 
this is usually followed by premature ovarian failure (34).  This area is incompletely understood.  
There are cases of spontaneous pregnancy in women with non-mosaic Turner’s syndrome, 
indicating a presence of mature ovarian follicles in some women with this genotype (35).  There 
has been much interest recently in cryopreservation of oocytes or ovarian tissue in these 
women whose fertility may be reduced in later life (36). 
A recent study investigated low levels of X-monosomy mosaicism in 1000 young women (mean 
age 25) with spontaneous POF and no clinical signs of Turner’s syndrome using karyotype and 
FISH (interphase flourescent in situ hybridisation) techniques.  It found chromosome 
abnormality rates of 14% in women with primary amenorrhoea and 8% with secondary 
amenorrhoea using karyotype alone.  The FISH technique was used to detect low levels of 
45XO/46XX mosaicism and found that 11.5% of POF patients with a normal karyotype had an 
increased rate of mosaicism (37).   
2.1.2.1.3 X chromosome gene defects 
As well as a complete lack of part of an X chromosome, gene defects can also cause ovarian 
failure.  Two regions on the X chromosome named POF1 and POF2 have been identified as 
necessary for normal ovarian function.  POF1 is found at Xq13-Xq26 and is of maternal origin.  
POF2 is found at Xq13.3-q21.1 and is of paternal origin (38).  Disruption of these genes, 




The bone morphogenic protein-15 (BMP15) is a protein coded on the long arm of the X 
chromosome (Xp11.2) which is expressed in the oocyte during folliculogenesis.  It has been 
found in vitro and in animal models to have a positive effect on folliculogenesis.  Studies of the 
BMP15 gene in the POF population have found mutations in up to 10% (39).   
2.1.2.1.4 Autosomal mutations 
Autosomal mutations can also be associated with POF.  These include mutations of the 
phosphomannomutase 2 gene, the FSH receptor gene, the galactose-1-phosphate 
uridyltransferase gene, the blepharophimosis gene, and the autoimmune regulator gene.  
Several of these mutations cause enzyme deficiencies which are serious or potentially lethal – 
for example carbohydrate-deficient glycoprotein syndrome type 1 caused by a lack of 
phosphomannomutase.  A lack of galactose-1-phosphate uridyltransferase causes 
galactosaemia, which causes a reduction in germ cell development during fetal oogenesis, 
presumably due to the toxic effect of galactose (40).  Mutations in the FOXL2 gene on 
chromosome 3 cause blepharophimosis ptosis epicanthus inversus syndrome (BPES).  BPES 
type 1 but not BPES type 2 is associated with POF.  The autoimmune regulator gene is 
responsible for autoimmune polyendocrinopathy candidiasis actodermal dystrophy, of which 
POF can be a part.   
Inhibin is produced by granulosa cells and acts to reduce FSH secretion by the pituitary in a 
negative feed-back fashion.  It also has actions in the ovary itself, including stimulation of 
androgen synthesis in thecal cells and regulation of follicle growth.  These roles led to it being 
considered as a candidate gene for POF and mutations in the inhibin gene have been linked to 
POF in some populations (41).   
2.1.2.2 Autoimmune cause 
30% of cases of POF are estimated to be due to autoimmune disease (22).  However, this may 
vary depending on the age of patients seen and referral patterns; at Guy’s and St Thomas’ only 
3% have associated autoimmune disease (23).  There is no value in assessing anti-ovarian 
antibodies because these are also present in a large percentage of the general population (42).  
However, a positive anti-thyroid antibody result, which is found in approximately 24% of women 
with POF (43), and a family history of auto-immune disease, can be used to identify a presumed 
autoimmune aetiology.  It is also worthwhile testing for anti-adrenal antibodies to identify the 
small subgroup of women with POF who are at risk of developing Addison’s disease (44, 45).  
This is especially important if egg donation is being pursued because of the danger of cortisol 
deficiency in pregnancy.   
2.1.2.3 Idiopathic premature ovarian failure 
The mechanism of most cases of spontaneous POF is unknown.  A reduced initial number of 
oocytes, accelerated oocyte atresia and follicular dysfunction have been suggested.  POF is 




unpredictable.  Pregnancy may occur, sometimes many years after diagnosis (3), and studies 
monitoring ovarian activity have shown that over 80% have ovarian follicular activity and almost 
50% ovulate (4).   
Histological data has shown a large variation in follicle numbers at different ages.  Due to the 
nature of the rate of follicular decline, it appears that the number of initial oocytes would need to 
be very significantly reduced to cause POF.  Using their model for follicular depletion, Faddy et 
al estimate that a loss of 90% of follicles before the age of 14 would result in the menopausal 
threshold of 1000 follicles at the age of 27 (46).  However, studies have shown that in women 
who go through the menopause at the usual time very few if any follicles are left post-
menopause (47) and this theory would not explain cases where pregnancy has occurred in 
women with POF many years after the diagnosis.   
2.1.3 Secondary premature ovarian failure 
Premature ovarian failure can occur following treatment with certain types of chemotherapy or 
radiotherapy which damage ovarian tissue.  Abdominal radiotherapy and the protocols required 
prior to bone marrow transplantation are associated with high rates of permanent ovarian failure.  
Alkylating agents have a detrimental effect on ovarian function in the longer term (48).  Ovarian 
function post treatment appears to be more favourable in pre-pubertal than post-pubertal girls 
(48).  Methods used to reduce rates of ovarian damage include concurrent treatment with 
gonadotrophin releasing hormone agonists, the mechanism of action of which is unknown, and 
transposition of the ovaries.  Cryopreservation of oocytes, embryos or ovarian tissue may also 
be options to preserve future fertility.   
Infections can also cause ovarian failure.  Mumps has long been recognised as a potential 
cause, although the ovarian failure may be transient (38, 49).  HIV infection is a relatively newly 
recognised cause (50).  Ovarian tuberculosis is also described as a cause of POF (38). 
Other treatments which may decrease ovarian reserve include those which have the potential to 
affect blood supply to the ovaries, such as hysterectomy with ovarian conservation, 
myomectomy and uterine artery embolisation.  A reduction in ovarian tissue, for example due to 
endometriosis, or the removal of endometriomas or other ovarian cysts, can also reduce ovarian 
reserve (51).   
Recent data from 4968 women born in a single week in 1958 revealed that POF by the age of 
40, either spontaneous or iatrogenic, affected 7.4% of those followed up (52). 
2.2 Consequences of POF 
A low oestrogen level causes many unpleasant symptoms and in the long term has a 




2.2.1  Menopausal symptoms 
Menopausal symptoms are reported to affect approximately 70% of climacteric women (38). 
These include vasomotor symptoms (hot flushes and night sweats), vaginal dryness, low mood, 
decreased libido, lack of energy and irritability.  All of these can impact quality of life.  Oestrogen 
replacement effectively reduces most symptoms, especially vasomotor symptoms (53).  
The prevalence of most of the symptoms of oestrogen deficiency in the spontaneous POF 
population and the effects of treatment has not been studied.  It is possible that there are 
differences in initial symptoms compared with the older group of women due to intermittent 
ovarian function.  Depression and sexual function are the best studied symptoms, but data on 
the impact of treatments or the natural course of the disorders is lacking.   
A questionnaire study conducted in 2000 in a London teaching hospital investigated 
‘psychological well-being’ in 64 women with spontaneous POF and found depression scores 
comparable to a psychiatric in-patient population (14).  74% of respondents were classified as 
depressed.  Rates of depression decreased with increasing years since diagnosis but were 
unaffected by whether the woman already had a child or not.  Unfortunately there was a low 
response rate of 42%.  A more recent study in America assessed depression and other mood 
disorders in 174 women with POF using a structured clinical interview (54).  They also found 
high rates of depression in POF (67% of the POF sample had a mood disorder, mostly 
depression, compared with reported rates of 24% from community based studies).  This study 
also investigated the timing of onset of depression and found that in most women the diagnosis 
of depression came before that of POF but after menstrual cycle irregularity.  This could be 
explained by the theory of early ovarian insufficiency causing depression.  However the authors 
then compare their data with data collected in their unit from 100 women with Turner syndrome 
and found significantly lower rates of depression in the Turner syndrome group.  This led them 
to query whether POF and depression could share pathophysiology.   
Singer et al (2011) carried out a questionnaire study by post to women attending London clinics 
and online via the Daisy Network, assessing the psychosocial aspects of POF (55).  The 
response rate was 62% to the postal questionnaire and altogether 136 responses were 
analysed.  Quality of life was assessed using the Short Form-36 (SF-36) questionnaire and 
found that compared with normative data, women with POF had worse mental and physical 
health and rated their quality of life as relatively low.  A negative impact on self-image and 
confidence was also reported.  The 1958 Birth Cohort study also found that women with both 
iatrogenic and spontaneous POF had a reduced SF-36 quality of life score (52). 
Two studies have been carried out assessing the effect of HRT on symptoms in women with 
iatrogenic POF.  A questionnaire study of 89 women who had early menopause secondary to 
radiotherapy or chemotherapy indicated that women choosing to take hormone treatment (type 
not specified) have a lower menopausal symptom score and better physical component of 
quality of life score (assessed by SF-36), as compared with those not taking treatment (56).  




Another study of 31 women with chemotherapy-induced POI (mean age 36) investigated the 
effect of HRT in those women who were happy to take it (15/31) (57).  Compared with those 
who did not take HRT, this group had a significant reduction in hot flushes, insomnia and 
psychological and emotional changes (all improved in 66%), vulvo-vaginal and skin atrophy 
(53%), genito-urinary disturbances (53%) and musculskeletal symptoms (53%). 
Decreasing stigmatisation, goal readjustment, positive affect and education about the condition 
have all been identified as factors which can contribute to emotional well-being in POF (58).   
Questionnaire studies indicate that women with POF have lower sexual satisfaction and sexual 
function scores than controls (15, 59).  50% of these women who completed the Short Personal 
Experiences Questionnaire in the Singer et al study were classified as experiencing sexual 
dysfunction and responsiveness to sex was a worry to 64% (55).  Kalantaridou et al (2008) 
assessed sexual function score in 143 women with POF following 3 months of physiological 
oestrogen replacement (100mcg oestradiol patch) (59).  Despite adequate oestrogen 
replacement 7% of the POF group, compared with 2% of the control group, had an abnormal 
composite sexual function score (p<0.001). The authors do not report the scores at the start of 
the hormone replacement period, although prior to starting HRT there was only a very short 2 
week washout period from any previous regimens used so this data would be of limited value.  
15% of women with POF had a free testosterone below the normal limit and 5% had total 
testosterone below normal; both these groups had a trend towards lower sexual function 
scores.  There was a significant correlation between sexual function score and total 
testosterone in POF (p=0.03) and a trend to correlation with free testosterone (p=0.06).  These 
associations were not seen in the control group.  Van der Stege et al (2008) conducted a 
questionnaire study of 81 women with POF (response rate 41%) (15).  Women with POF were 
found to be less satisfied with sexual aspects of their life and had less sexual motivation than 
controls.  Women with POF taking oestrogen replacement were found to have lower levels of 
sexual satisfaction than those not using oestrogen replacement.  However, there could be a 
bias towards women with more significant symptoms opting to take treatment.  Total 
testosterone increased the frequency of desire for sexual contact but no other parameters.  
Both of these studies measured testosterone levels but the value of this in isolation is uncertain; 
it is recognised that androgen metabolism is complex and serum levels may not reflect tissue 
levels (60).  However, several studies have found that testosterone levels are reduced in POF 
(61).  Another recent cross-sectional study confirmed high rates of sexual dysfunction in POF: 
62% in the POF group (n=58) and 38% in the control group (n=58) were classified as having 




2.2.2 Long term complications of POF 
2.2.2.1 Osteoporosis 
2.2.2.1.1 Definition and DXA 
The World Health Organisation (WHO) defines osteoporosis as ‘a systemic skeletal disease 
characterised by low bone density and micro-architectural deterioration of bone tissue with 
consequent increase in bone fragility’ (63).  Diagnosis is made by a T score ≤-2.5 measured by 
dual energy X-ray absorptiometry (DXA) scan at the lumbar spine, hip or radius (forearm).  The 
T score is the number of standard deviations the bone mineral density (BMD) differs from the 
young adult mean, adjusted for gender and ethnicity.  Central DXA (lumbar spine or hip) is 
preferred as it assesses the sites of most clinical relevance and is proven to predict fracture risk 
(64).  The most powerful predictor of fracture is hip DXA.  The best site for monitoring response 
to treatment is the lumbar spine due to good precision and relatively large changes with 
treatment (64).   
 T-score 
Normal T ≥ -1.0 
Osteopaenia -2.5 < T < -1.0 
Osteoporosis T ≤ -2.5 
Established osteoporosis T ≤ -2.5 plus one or more fragility fractures 
Table 2 World Health Organisation definitions of osteopenia and osteoporosis 
The Z score is the number of standard deviations the BMD differs from an age, gender and 
ethnicity matched mean.  It therefore gives a measure of the patient’s BMD compared with that 
expected for his or her age group.  Z scores are used in preference to T scores in individuals 
who have not yet reached peak bone mass.   
2.2.2.1.2 Clinical consequences of osteoporosis 
The clinical consequence of osteoporosis is fracture, which occurs at lower trauma in 
osteoporotic bone than in healthy bone.  For each standard deviation the BMD drops below the 
young adult mean, the risk of sustaining a fracture doubles (65).  The most common fractures 
associated with osteoporosis are those of the hip, vertebrae and wrist (63).  All are associated 
with a reduction in quality of life, with a higher impact caused by hip fracture, vertebral fracture 
or fracture at more than one site (66, 67).  Excess mortality rates in the year following a hip 
fracture, compared with the general population, have been reported as up to 36%.  Most studies 




BMD is not the only predictor of fracture; half of all fractures occur in individuals who do not 
have osteoporosis (69).  Fracture risk appears to depend on bone quality as well as density and 
many risk factors have been identified.  An assessment of absolute risk of fracture can be 
estimated in women over 40 using the FRAXTM model, which has been developed from meta-
analysis of risk factors and calibrated to the UK population (70).  It estimates an individual’s risk 
of hip fracture and major osteoporotic fracture over the next 10 years, based on the following 
clinical information, with or without femoral neck BMD: 
- Age 
- Gender 
- Body mass index (BMI) 
- Prior fragility fracture 
- Parental hip fracture 
- Current smoking 
- Long-term glucocorticoid use 
- Rheumatoid arthritis 
- Secondary cause of osteoporosis (only included in calculation if BMD unknown) 
- Daily alcohol intake 3 or more units 
Unfortunately, due to a lack of epidemiological data in younger age groups, the FRAXTM model 
cannot be used to estimate fracture risk in a person under the age of 40 years.   
2.2.2.1.3 Pathophysiology of osteoporosis 
Bone mass increases throughout childhood and adolescence and reaches a peak at the age of 
20-30.  In women the rate of gain in BMD reduces significantly after menarche.  The 
development of osteoporosis depends on both the peak bone mass attained, which is highly 
variable (63), and subsequent loss.   
Determinants of peak bone mass include (71): 
- Genetic factors, the exact nature of which are unknown, but are likely to be polygenic 
- Gender 




- Endocrine factors, for example GH deficiency, oestrogen deficiency due to anorexia or 
weight related amenorrhoea, hyperthyroidism 
- Physical activity 
In the healthy individual, peak bone mass is maintained until the fifth decade when a small 
amount of bone loss starts to occur.  Substantial loss occurs from the time of menopause in 
women, due to oestrogen deficiency.  After 6-10 years the rate of loss slows down (38).   
Bone is a dynamic tissue and undergoes remodelling in 3-6 month cycles.  Each year 
approximately 5-10% of the adult skeleton is remodelled.  This process repairs microdamage 
throughout the skeleton and maintains bone structure and strength.  In the normal state, bone 
formation matches resorption.  It is controlled by local and systemic hormones and immune 
cells.  Remodelling takes place in bone remodelling units which consist of osteoclasts and 
osteoblasts.  The bone remodelling unit is encased by a ‘canopy of cells’, which may contribute 
towards creating the correct microenvironment (72).  Osteoclasts resorb bone then osteoblasts 
lay down organic bone matrix and mineralise it.  This is a highly co-ordinated process and the 
exact control mechanisms are incompletely understood.  Osteoblasts have a role in controlling 
the differentiation of osteoclasts through the expression of osteoclastogenic factors.  
Macrophage colony stimulating factor (M-CSF) and receptor activator nuclear factor-ĸB ligand 
(RANKL) are essential osteoclastogenic cytokines produced by bone marrow stromal cells and 
osteoblasts.  Osteoblasts and bone marrow stromal cells also produce osteoprogenin (OPG) 
which binds to RANKL receptors and inhibits the effects of RANKL.  Immunological factors also 
play a role: T cells produce interferon, tumour necrosis factor α (TNFα) and RANKL which 
increase osteoclastogenesis (73).  B cells produce OPG.  B cell deficiency in mice causes 
osteoporosis (72).  Megakaryocytes in the bone marrow express RANKL and OPG and may 
also influence remodelling (72).  Osteocytes are differentiated osteoblasts which are engulfed in 
bone matrix.  They have long dendrites which extend through the matrix and are believed to 
play a role in detection of mechanical strain and direction of remodelling (72).   
Systemic hormones which act on bone remodelling units include parathyroid hormone (PTH), 
oestrogen and thyroxine.  PTH is secreted by the parathyroid glands in response to a low serum 
calcium.  It acts via osteoblast receptors to induce osteoclast differentiation and therefore 
increase bone resorption.  Hyperthyroidism increases the rate of bone turnover and excess 
glucocorticoid treatment reduces bone formation (63).  Oestrogen has both direct skeletal and 
extra-skeletal effects, which are discussed below.   
2.2.2.1.4 Effect of oestrogen on bone and bone mineral density 
Oestrogen acts on bone cells directly and via cytokines. The current understanding of its effects 
are: (74)  




2. Promotes apoptosis of osteoclasts and inhibits differentiation 
3. Prevents apoptosis of osteoblasts and promotes differentiation 
Evidence for inhibition of activation of bone remodelling units comes from histological and bone 
turnover marker data following administration of oestrogens to postmenopausal women (75).  
Oestrogen stimulates osteoblastic OPG production which inhibits RANKL and therefore inhibits 
osteoclastogenesis.  Oestrogen deficiency causes an increase in RANKL production by bone 
marrow stromal cells and osteoblasts, which increases osteoclastogenesis (73).  The 
importance of oestrogen in maintaining bone formation is seen following a short period of 
oestrogen deficiency, which causes a rapid decrease in bone formation markers (76).  
Extra-skeletal effects of oestrogen deficiency are: decreased intestinal calcium absorption, 
increased renal excretion and an increase in PTH levels (73).  
Oestrogen also plays a vital role in the development and maintenence of the male skeleton.  
Men who are oestrogen deficient from childhood have delayed epiphyseal fusion, low bone 
density and high bone turnover markers (74).  In adult men oestrogen plays a role in regulation 
of bone formation and resorption and determines bone mass and bone loss (74).   
An accelerated phase of bone loss due to oestrogen deficiency occurs in the early post-
menopausal years, with subsequent slowing to a rate seen in older men.  Numerous studies 
have shown that HRT prevents bone loss (77).  The Women’s Health Initiative trial found that 
HRT reduces hip and vertebral fractures by one third; other fractures were also reduced (78). 
The effects of the COCP at the menopause have been much less widely studied.  A few small 
studies indicate that it maintains or slightly increases BMD (79, 80).   
2.2.2.1.5 Bone mineral density in premature ovarian failure 
Several cross-sectional studies have shown that women with POF have reduced bone density 
(7, 8, 81).  The largest included 442 women aged 18-42 with spontaneous POF (6).  70 
concurrent regularly menstruating controls were used along with 353 matched controls from 
NHANES III (National Health and Nutrition Examination Survey).  The POF group were found to 
have significantly lower BMD at the lumbar spine and hip of 2-3%.  8% of the women with POF 
had a T score of -2.5 or less (within oesteoporotic range) and 15% had a Z score of under -2 
(below the expected range for their age).  A Z score of under -2 was significantly associated 
with: not taking HRT, delay in diagnosis of over a year, onset of irregular periods before age 20, 
lack of regular exercise, low calcium intake and low serum vitamin D.  The authors also looked 
at the type of prior oestrogen replacement (HRT (n=184), COCP (n=68), HRT/COCP in either 
order (n=61)) although not the preparation, dose or length of time taken and found no 
differences in BMD between the groups.   
A cross-sectional study which included 4724 postmenopausal women, 582 (21%) of whom had 




increased risk of fracture (odds ratio for fracture 1.5; CI 1.2-1.9) (10).  A recently reported 
retrospective observational study followed 390 women from the ages of 48 to 84 and assessed 
bone density, fractures and mortality from all causes (82).  The authors found that those with 
menopause before the age of 47 had significantly higher risks of osteoporosis at the age of 77 
(RR 1.83; 95% CI 1.22-2.74), risk of fragility fracture by the age of 84 (RR 1.68, 95% CI 1.05-
2.57) and mortality by 84 (RR 1.59; 95% CI 1.04-2.36) compared with those who had 
menopause later than 47 years.   
To date there is only one published prospective trial which has investigated bone density with 
different oestrogen preparations in women with POF (83). This was a small open-label 
randomised crossover trial.  Following a 2 month ‘washout’ period participants were randomised 
to either ‘physiological’ or ‘standard’ hormone replacement.  The physiological regime consisted 
of transdermal oestradiol (100mcg week 1 and 150mcg weeks 2-4) with 200mg progesterone 
vaginally twice a day in weeks 3-4.  The standard regime was equivalent to a standard strength 
COCP – 30mcg ethinyloestradiol with 1.5mg norethisterone daily for weeks 1-3 then a pill free 
week in week 4.  The authors report a significant increase in Z score following a year’s 
treatment with the physiological regimen but no difference with the COCP.  However, when the 
change in BMD was directly compared between the two groups no significant difference was 
found.  Interestingly, although both regimens suppressed the marker of bone resorption (CTX), 
the markers of bone formation (bone ALP and P1NP) were increased following the physiological 
treatment but decreased following COCP.  CTX was suppressed significantly more by the 
COCP than by the physiological regimen.  Both treatments suppressed FSH and LH by a similar 
amount.  The drop-out rate in this study was high with only 18/34 completing the trial.  Most of 
the women did not have spontaneous POF – of those who completed 4 had POF secondary to 
cancer treatment, 7 had Turner syndrome and 7 had idiopathic/surgical POF (the exact number 
with idiopathic POF is not provided). 
Bone health is reported as a major concern to women with POF; 92% in a recent questionnaire 
study were concerned about it, which was as high as the number with fertility concerns (55). 
2.2.2.1.6 Markers of bone turnover 
Bone turnover markers are divided into markers of bone formation and markers of bone 
resorption.  They change more quickly than BMD following initiation of treatment and are 
indicative of future BMD changes (84).  Bone resorption markers are independent predictors of 
fracture risk (85).   
P1NP (procollagen type I N-terminal propeptide) and CTX (cross-linked C-terminal telopeptide) 
are markers of bone formation and resorption respectively.  More than 90% of the organic bone 
matrix is made up of type 1 collagen.  This is constructed from type 1 procollagen and P1NP is 
a specific marker for type 1 collagen deposition, increasing when new bone is formed.  CTX is a 
type 1 collagen fragment and so levels are increased when bone resorption increases.  The 




At the menopause, bone turnover markers increase and remain elevated.  A reduction of up to 
70% is seen with HRT (85).  The effect of the COCP has been less widely studied but it has 
been reported to decrease markers of bone turnover in women aged 35-49 (86).  A very short (6 
month) crossover study of 17 women with Turner’s syndrome found the COCP to decrease 
bone formation markers whereas HRT did not (87).  The crossover study described above 
found that both the COCP and HRT decreased CTX but markers of bone formation were 
increased by HRT and decreased by the COCP (83). 
2.2.2.2 Cardiovascular disease  
For many years, it was considered that HRT decreased the risk of developing cardiovascular 
disease (CVD), based on data from observational studies, including the large Nurses’ Health 
Study involving 116,258 women, in which a 33% reduction was seen in those initiating HRT 
close to the menopause (88). This association was not confirmed in the initial Women’s Health 
Initiative (WHI) publications, which reported that combined HRT increases coronary heart 
disease by 29% (78). The WHI was a large randomised controlled trial investigating HRT as 
primary prevention for CVD.  The mean age of the trial participants was 63 years, 34% had a 
BMI of over 30 and HRT was commenced without a clinical reason, at a higher dose than would 
usually be used in this older age group.  Therefore, the applicability of these results to the 
general early postmenopausal population has been widely questioned, and the results cannot 
be generalised to women with POF.    
Oestrogen is considered to confer no overall benefit to women with established cardiovascular 
disease and may cause an early increase in risk.  This was evaluated in the Heart and 
Estrogen/Progestin Replacement Study (HERS) which randomised 2763 women with 
cardiovascular disease to either continuous combined HRT or placebo (89).  After a mean 
follow up of 4.1 years there was no difference in myocardial infarction or death secondary to 
coronary heart disease.  Although there was no overall difference in events between the groups, 
in the HRT group there were more events in years 1 and 2 and fewer in subsequent years, 
suggesting an early increase in risk with possible later benefit.   
The WISDOM trial (Women’s International Study of long Duration Oestrogen after Menopause) 
(90) initially aimed to investigate the use of HRT in younger women (age 45-60), which is the 
usual age of commencing HRT in clinical practice, for 10 years.  However, this was extended to 
69 years and the final mean age of participants was 63 years.  Findings were similar to the WHI 
trial, with an increase in cardiovascular and thrombo-embolic events in the combined HRT 
compared with the placebo group.  The trial was stopped early following the initial publication of 
the WHI results in 2002.  4385 women were randomised (26% of the original target) and 
followed for a mean of 11.9 months.  The short follow up and advanced age of participants 
meant that trial was unable to answer the original question of quantifying the health risks and 
benefits for women who start HRT around the time of the menopause.  A trial large enough to 
evaluate this specifically has not yet taken place and is not planned.  However, a meta-analysis 




reduction in coronary heart disease in women starting HRT before the age of 60 or within 10 
years of the menopause (91). The same team have more recently evaluated the relationship 
between hormone therapy and mortality in women under 60 using data from 19 randomised 
trials involving 16,000 women and found a significant reduction in mortality in women using HRT 
(92).   
A re-analysis of the WHI data showed that in women under 60 and those who commenced HRT 
within ten years of the menopause, there was a trend towards cardiovascular benefit (93).  The 
trial was discontinued before statistical significance was reached.  This correlates with results 
from the meta-analysis described above and with knowledge about the direct effects of 
oestrogen on the cardiovascular system.  Results from the Danish Osteoporosis Prevention 
study also support this.  This was an open-label trial in which women with an average age of 50 
and time since menopause of seven months were randomised to HRT or no treatment.  After 
ten years, there was a reduction in cardiovascular events in the HRT group (hazard ratio 0.48; 
95% CI 0.26 to 0.87) (94).  Oestrogen has been reported to have a beneficial effect on 
endothelial function in younger post-menopausal women, and to reduce atherosclerosis in 
oophorectomised monkeys (95).  There has been one cohort study which aimed to assess the 
association between early menopause, taking oestrogen replacement and the risk of ischaemic 
heart disease (96).  This study included 10533 postmenopausal Danish nurses aged over 44 in 
1993 (86% response rate) who gave their age at menopause via questionnaire and were then 
followed up via the national registry for cardiovascular events.  The findings were that 
menopause both at under 40 and under 45 were associated with increased ischaemic heart 
disease; this was most pronounced with surgical menopause but also seen in POF.  In women 
with surgical menopause who took HRT there was no increased risk of IHD compared with 
women who did not have early menopause.   
2.2.2.2.1 Cardiovascular disease in premature ovarian failure 
Epidemiological studies have associated an earlier menopause with increased cardiovascular 
risk.  A recent meta-analysis reported that the risk of developing CVD is increased by 38% in 
women who experience an earlier menopause compared with those who reach it at the age of 
50 (11).  A previous study suggested that for each year the menopause is delayed, the risk of 
cardiovascular mortality decreases by 2% (12).  No studies to date have examined the effect of 
an early menopause and oestrogen replacement on direct CVD outcomes.  It is recommended 
that women with POF take hormone replacement to reduce the risk of CVD (97) but this is not 
evidence-based.   
Kalantaridou et al (2004) investigated endothelial function in 18 women with POF (98).  The 
POF group had significantly lower flow-mediated vasodilation (FMD; a measure of the function 
of the endothelium in response to arterial occlusion) than controls.  This was normalised after 6 
months of HRT.  The COCP was not investigated.  Another study investigating FMD in 20 
women with POF not taking any hormone replacement also found that FMD was reduced 




study also had a lower level of circulating endothelial progenitor cells and increased carotid 
intima media thickness compared with controls, as well as impaired left ventricular diastolic 
function assessed by echocardiogram (99).  Goldmeier et al compared the endothelial function 
of 17 women with POF taking daily conjugated oestrogens and cyclical medroxyprogesterone 
acetate with 15 controls.  FMD was similar in the two groups but the POF group had slightly 
higher diastolic and systolic mean arterial pressures, although only the diastolic pressure was 
significantly different.  The POF group also had impaired baroreflex sensitivity and reduced 
heart rate variability (measures of autonomic response and possible markers of cardiovascular 
disease) compared with the control group (100).   
Langrish et al (2009) conducted a crossover trial to assess the effects of two different hormone 
replacement regimes in POF on blood pressure and renal function (101). Loestrin 30 (a COCP 
containing ethinyloestradiol and norethisterone) was compared with an oestradiol patch plus 
cyclical progesterone in a crossover trial.  Blood pressure was found to be slightly lower with the 
oestradiol patch compared with COCP.  However, follow up was poor with 18/42 completing the 
study.  Very few of the participants had spontaneous POF; most participants had 
chemotherapy-induced POF or Turner syndrome.  The type of progesterone given with the 
oestradiol was also variable, depending on participant choice of route of administration. 
2.2.2.2.2 Lipids 
After the menopause, there is an unfavourable change in lipid profile, with an increase in total 
and LDL cholesterol and triglycerides (TG) and a decrease in HDL cholesterol (102). 
It has been proposed that a change in lipid profile contributes to the increased cardiovascular 
risk associated with POF.  A cross-sectional study of 90 women with POF found slightly higher 
TG and borderline lower HDL compared with controls.  No relation to serum oestradiol levels or 
duration of oestrogen deficiency was found (13).  The effect of 6 months’ oestrogen treatment 
on lipid profile in POF has been investigated in two small studies.  A crossover study of 17 
women with Turner’s syndrome comparing the effects of an ethinyloestradiol-containing COCP 
with an HRT preparation of conjugated equine oestrogen and medroxyprogesterone acetate 
found no difference in lipid profile following 6 months of either treatment (87).  In their study of 
18 women with spontaneous POF, Kalantaridou et al (2004) found that there was no difference 
in the baseline lipid profile compared with controls, but after 6 months of HRT the LDL 
significantly decreased and TG increased compared with pre-treatment values although there 
was still no significant difference from the control group (98).   
2.2.2.2.3 C-reactive protein (CRP) 
CRP is an acute inflammatory marker.  Part of the pathogenesis of atherosclerosis and 
subsequent cardiovascular events is considered to be inflammatory and therefore CRP has 
been used to attempt to quantify cardiovascular risk.  High sensitivity CRP (hsCRP) is a strong 
predictor of cardiovascular events, even after adjusting for established risk factors, and has 




increases with hormone replacement therapy but remains a predictor for CVD (105).  However, 
other studies have questioned the value of CRP as an independent cardiovascular risk factor.  
One study investigating cardiovascular risk factors with oestrogen treatment found that CRP 
was increased whereas other markers such as interleukin-6 are not, leading to the question of 
whether the raised CRP is due to hepatic metabolism of the oestrogen rather than endothelial 
dysfunction (106).  This concern has been raised previously (107).  A recent study investigated 
baseline CRP levels and progression of atherosclerosis in 423 postmenopausal women over 
almost 3 years (108).  There was no relationship between initial CRP levels and progression of 
atherosclerosis, although a relationship between CRP and cardiovascular death/myocardial 
infarction was demonstrated.  Interestingly, CRP has also been reported as variable through the 
menstrual cycle (109).   
2.2.3 Fertility 
Loss of fertility is reported as one of the most distressing aspects of POF, especially with 
increasing age (14, 55, 110).  However, spontaneous pregnancy following diagnosis is 
estimated to occur in 5-10% (3).  There are many published case reports on pregnancy in POF.  
These include reports on the occurrence of pregnancy with no treatment (n=11), oestrogens 
(n=32), clomiphene citrate (n=1), corticosteroids with oestrogens (n=3), gonadotrophins (n=1) 
and gonadotrophin releasing hormone agonists with human menopausal gonadotrophin (n=2) 
(3).  A large number of reported pregnancies were in women not taking any treatment, leading 
to doubt over whether the interventions actually played a role in those women receiving 
treatment who became pregnant.   
There has been little good quality research in this area.  Interventions assessed in controlled 
trials include oestrogens with gonadotrophin releasing hormone agonists or danazol; 
gonadotrophin releasing hormone agonist plus gonadotrophins and oestrogen replacement 
therapy. None produced a higher pregnancy rate than the background observed rate.  Studies 
to date are limited by their small size, short follow up periods, wide variations in inclusion criteria 
and few randomised controlled trials.  Many studies have used ovulation rather than pregnancy 
as an endpoint.   
It is impossible to accurately predict which women will conceive spontaneously.  A shorter 
duration of amenorrhoea has been identified as a positive prognostic factor (3).  Autoimmune 
aetiology of POF and the presence of ovarian activity on ultrasound scan have also been 
suggested to be associated with a higher chance of spontaneous conception (111). 
Dehydroepiandrosterone (DHEA) has recently been postulated as a treatment for POF and has 
been claimed in individual cases to reduce FSH levels and lead to pregnancy (112, 113).  It is 
an androgen synthesised in the adrenal gland and ovary and is a precursor for ovarian sex 
hormone synthesis.  However, there have been no controlled studies to assess its efficacy in 
POF, although one is underway (114), and there is no theory on its potential mode of action.  It 
is a prescription-only medication in the UK and is not widely available.  In America it can be 




The only effective fertility treatment option is in vitro fertilisation with egg donation.  This carries 
good outcomes, dependent on the age and appropriate selection of the egg donor.  Clinical 
pregnancy rates following egg donation are reported to be around 30% (115).  A small study in 
which one group consisted solely of women with POF (36 women) demonstrated an average 
requirement of 1.75 cycles for a live birth and a cumulative pregnancy rate of 75% (116).   
Fertility preservation for women at risk of developing POF is a topical area.  Currently, embryo 
freezing carries the highest chance of success but this is only an option for women with a 
partner or who wish to use donated sperm.  Oocyte freezing has low rates of success of 5-10% 
chance of a live birth (117) but this may improve with newly developed techniques of rapid 
freezing.  A case of a 14 year old with mosaic Turner syndrome opting for oocyte freezing is 
described (36).  Ovarian tissue cryopreservation prior to chemotherapy or radiotherapy and 
auto-transplantation following treatment has recently been developed and pregnancies are 
reported (118). 
As described above, follicular activity and ovulation are observed in POF (3, 4), making it 
different from the ‘normal’ menopause.  The term ‘ovarian reserve’ indicates the number and 
quality of remaining oocytes.  The only way to definitively determine this would be to examine 
the whole ovary histologically.  Obviously this is not desirable and so indirect markers of the 
ovarian reserve have been developed.  These markers are used in assisted conception to 
predict response to ovarian stimulation.  Potential uses in POF include diagnosis, predicting 
women who may respond to fertility treatment, predicting future ovarian function and improving 
understanding of pathogenesis.  To date, few studies have investigated a combination of 
markers of ovarian reserve in POF and none have examined any markers longitudinally.   
2.2.3.1 Ovarian reserve markers 
The traditional marker of ovarian reserve is serum follicle stimulating hormone (FSH) 
concentration which is produced by the pituitary and stimulates the growth of new follicles in the 
ovary.  However, FSH is not an ideal marker: it must be correctly timed in order to be 
interpreted, it has a high cycle-to-cycle variability, only increases in the later stages of ovarian 
ageing and is poor at predicting reproductive status (119). In one study, 11% of 112 women with 
confirmed POF and not currently taking oestrogen replacement had an FSH level lower than the 
criteria for diagnosis (120).  Attention has turned to more direct markers, originating from the 
ovary itself. 
2.2.3.1.1 Antral follicle count  
In a normal monthly menstrual cycle, approximately ten oocytes from each ovary are selected to 
develop as follicles.  These are called antral follicles and can be counted on trans-vaginal 
ultrasound scan.  One follicle is eventually selected to become the dominant follicle.  The 
dominant follicle continues to grow and will ovulate in response to a surge of luteinising 
hormone (LH) when it has reached an appropriate size.  The antral follicle count (AFC) is 




proven.  It is a strong predictor of ovarian response to stimulation and the pattern of decline in 
AFC with age fits with the decline in numbers of primordial follicles (121).  The AFC is 
independent of the time of the menstrual cycle (122, 123).  
2.2.3.1.2 Ovarian volume 
Ovarian volume decreases with age and has therefore been used as a marker of ovarian 
reserve (124). Compared with AFC, it is a poorer predictor of ovarian response to stimulation 
(125).  However, it is easy to measure and may be useful in contributing to predictive models in 
POF (126).  
2.2.3.1.3 Anti-Müllerian hormone  
Anti-Müllerian hormone (AMH) is a glycoprotein peptide growth factor and a member of the 
TGF-β (transforming growth factor-beta) family.  Its name is derived from its role in the male 
fetus, where it is produced by Sertoli cells to cause regression of the female Müllerian duct 
system.  AMH is expressed in antral follicles from the stage of primordial follicle recruitment until 
selection for dominance.  It is therefore indicative of the number of growing antral follicles (127).  
Mouse studies suggest that plasma AMH acts as an intra-ovarian signal for the size of the antral 
follicle pool and enables its regulation; lack of AMH causes accelerated follicular recruitment 
and exhaustion (128).  Unsurprisingly, AMH is related to AFC.  AMH can be measured at any 
stage of the menstrual cycle and unlike AFC is completely operator-independent.  AMH is as 
good as AFC at predicting poor response to ovarian stimulation in IVF (129).   
There is interest in using ovarian reserve markers, and in particular AMH, to predict the age at 
menopause.  The theory is that, in a similar way to the menopause occurring when the 
threshold of around 1000 follicles is reached, there is a threshold AMH level at which 
menopause occurs.  If the pattern of decline of AMH is known then the age at menopause could 
theoretically be predicted.  A cross-sectional study investigating serum AMH in 144 fertile 
women demonstrated a relationship between AMH levels and the population’s pattern of age at 
menopause (130).  However, to date no ovarian reserve marker has been found to accurately 
predict age at menopause (131).  The study included few young women making predictions of 
menopausal age based on AMH for young women even more uncertain.   
2.2.3.1.4 Inhibin B 
Inhibin B is also a glycoprotein of the TGF-β family.  It is produced by granulosae and thecal 
cells in small antral follicles and inhibits FSH secretion.  Its concentration is related to the mass 
of granulosa cells, leading to its use as a marker of ovarian function.  Inhibin B increases until 
the mid-follicular phase and then decreases in inverse correlation with FSH; measurement must 
therefore be correctly timed at the beginning of the follicular phase.  Inhibin B serum 
concentrations decrease before FSH increases with age-related decline of ovarian function.  




2.2.3.2 Ovarian reserve markers in POF 
Few studies have been carried out in this area.  An early study (in 2006) measured serum AMH 
levels and small antral follicles in 12 women with POF and found both to be significantly 
reduced compared with healthy controls and women with hypogonadotrophic hypogonadism 
(133).  10 women with POF had undetectable AMH levels and 2 had very low levels (133).  
Knauff et al (2009) took a single measurement of AMH, inhibin B and AFC in 112 women with 
POF (FSH over 40IU/l), as well as groups with a regular cycle and with oligomenorrhoea, both 
with raised FSH (over 10.2 IU/l) (120).  They reported that AMH was a superior marker of the 
clinical stage of ovarian failure compared with AFC; inhibin B was the poorest.  AMH was 
detectable in 5% of women with POF and was below the 5th centile in all of these.  In the group 
with an FSH of over 10.2IU/l and oligomenorrhoea, 33% had a normal AMH; in the group with 
FSH of over 10.2IU/l and regular cycles, 75% had a normal AMH.  This leads to the theory that 
in some women who are developing spontaneous POF there is still a significant remaining 
ovarian reserve.  Another study which evaluated the AMH levels of 147 women with POF found 
a normal level in 5%, a level below normal in 18% and undetectable levels in 77% (24). 
Massin et al (2008) postulated that there may be either an absence of follicles or impaired 
follicle growth in POF (134).  They compared ovarian histology with serum inhibin B and AMH 
and found both to be predictive of the presence of follicles.  However, there is a flaw in 
regarding ovarian histology as a ‘gold standard’ for the presence of follicles: pregnancies in the 
absence of follicles on histology are well documented. 
No research to date has looked longitudinally at the progression of ovarian reserve markers in 
POF.  In order to rely on these markers for diagnosis, or to develop ways of using them in a 
fertility setting, we need to know this.  This study begins to address this, and in looking at 
several markers will aim to examine their inter-relation in this population. 
2.2.4 Treatment of POF  
Oestrogen replacement is recommended in POF to protect against bone loss and 
cardiovascular disease and alleviate symptoms.  The most suitable form is unknown and 
management is not currently evidence-based (1, 16, 17).  Currently, either HRT or the COCP is 
commonly prescribed.  A recent survey of 130 members of the British Menopause Society 
revealed that 56% prescribe HRT in preference to COCP and 23% have no preference (135).  
HRT is considered to be more 'physiological' but some young women dislike taking a 
preparation associated with older women.  The COCP contains synthetic oestrogen at a higher 
dose with a 'pill free' week.  It may be considered more 'peer friendly' than HRT (it is taken by 
16% of women aged 16-49 (136)) and there is no prescription charge.  The quantification of the 
relative advantages and disadvantages of each treatment in POF is important in order to 
provide evidence-based advice on treatment options.  Affected women face many years of 




There are also a significant proportion of women who decline treatment.  To date, there have 
been no prospective studies in POF investigating the quantitative effects on bone density or 
other outcomes of different treatments compared with no treatment.  In spite of the almost 
universal recommendation of oestrogen replacement, the number of women who decline 
treatment may be higher than often perceived.  There are no published studies estimating the 
number of women who decline oestrogen treatment in the long term.  A study in America 
investigating bone density in 442 women with POF included 92 (21%) who had never taken 
oestrogen replacement (6).  Another American study investigating 50 well-educated women with 
Turner’s syndrome found that only 68% were taking oestrogen replacement therapy in 
accordance with current guidelines (137).  Of the 16 women not taking oestrogen replacement, 
11 were not compliant with treatment and 5 had not been prescribed oestrogen replacement.  
The most important factor in predicting compliance with treatment was education about 
oestrogen replacement and bone health.  Another study of 89 women with POF due to 
chemotherapy or radiotherapy, of whom 43 were taking oestrogen replacement, asked an open-
ended question regarding views on oestrogen therapy (56).  26% were concerned about the risk 
of cancer, especially breast cancer; this may be high due to the nature of the group.  Concerns 
over weight gain were cited by 13%.  Reasons for taking oestrogen therapy included protection 
against osteoporosis (48%), replacement of hormones (29%) and relief of menopausal 
symptoms (24%).  It has been reported that many women with POF believe that adverse media 
reports regarding HRT apply to their age group (138).  Even after the provision of accurate 
advice, this may contribute towards a decision to decline treatment. 
2.3 Microgynon 30 and Nuvelle 
Microgynon 30 is a COCP containing ethinyloestradiol 30mcg and levonorgestrel 150mcg.  One 
pill is taken daily for 21 days followed by a 7 day break which induces a withdrawal bleed.  It is a 
popular first choice COCP.  Ethinyloestradiol is a synthetic oestrogen contained in most 
COCPs.  Levonorgestrel is a synthetic 19-nortestosterone derived progestogen.   
Nuvelle is a cyclical HRT consisting of oestradiol 2mg daily, with the addition of levonorgestrel 
75mcg for 12 days a month, producing a monthly bleed.  ‘Natural’ oestrogens such as oestradiol 
are increasingly popular.  Nuvelle was chosen for this study because it also contains 





Chapter 3 Methods 
3.1 Regulatory approvals 
Prior to starting the trial, I obtained Ethics, Medicines Healthcare Regulatory Agency (MHRA) 
and local Research and Development (R&D) approvals.  I completed the necessary forms via 
the Integrated Research Application System (IRAS) and EudraCT websites and attended Guy’s 
Research Ethics Committee meeting to answer queries.  Two small adjustments were 
recommended by the committee prior to final Ethics Committee approval. 
3.2 Recruitment 
Participants were recruited through the Premature Ovarian Failure (POF) and Menopause 
Clinics, the Reproductive Medicine Clinic, local GPs and The Daisy Network (a national patient-
run support group for women with POF). 
All potentially eligible women who had previously attended the POF/Menopause clinics were 
invited to participate by letter and telephone.  Women who attended as new referrals were 
approached in the clinic.  I wrote to local GPs to encourage them to refer any women who may 
be interested in participating. 
I visited local hospitals to publicise the trial.  The Daisy Network advertised the trial on their 
website and I attended their 2009 annual conference to talk about the trial.  The trial 
advertisement was also posted on the ‘Menopause Exchange’ website and published in their 
newsletter.  A circular e-mail was sent to King’s College London employees.  In November 
2010, the Joint Clinical Trials Office issued a press release to aid recruitment.  This resulted in 
coverage on BBC online, Women’s Weekly and the Daily Express.  The trial advertisement also 
featured on the Guy’s and St Thomas’ Foundation Trust Hospital intranet.   
Women interested in participating were provided with written information (the Participant 
Information Sheet) and given time to consider participation.  If appropriate and when possible, 
reasons for non-participation were sought and recorded.  Visits were arranged in the morning so 
that questionnaires were completed at a similar time at each visit and participants could fast 
prior to blood samples.   
3.3 Protocol 
Following written informed consent, women were seen for a screening visit.  A full medical 
history was taken and physical examination performed.  Blood was taken for repeat follicle 
stimulating hormone, thyroid function tests and fasting lipid profile as necessary.  Once the 
inclusion/exclusion criteria (see appendix 1) had been confirmed, the participant was enrolled 
into the study and assigned a study number.   
Each participant was seen at baseline and at 3, 6, 12, 18 and 24 months.  At the baseline visit, 
the participant decided whether she wanted to be in the ‘no treatment’ or ‘active treatment’ 
group.  Participants in the ‘active treatment’ group were randomised to Microgynon 30 




(oestradiol 2mg daily, plus levonorgestrel 75mcg for 12 days a month) using the secure internet 
randomisation website www.sealedenvelope.com.  It was not feasible to blind the participant or 
the candidate to the medication and this was therefore an open label study.  A supply of the 
study medication in its original packaging was provided at 6 monthly intervals.  The visit 
schedule below shows the investigations performed at each visit. 
All visits took place in the morning to allow an overnight fast prior to the blood test and to enable 
the questionnaires to be done at the same time of day on each occasion.  Unfortunately it was 
not possible to see participants at the same stage of the cycle for each visit, due to the 
constraints of organising bone scans and the flexibility needed by the participants, most of 
whom were working full time or looking after young children.  At each visit, enquiries were made 
about adverse events and changes to medications or new medications, including over the 
counter preparations.  General multivitamins were allowed but women were asked not to take 
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1Menopause Symptoms–Treatment Satisfaction Questionnaire  
2Brief Profile of Female Sexual Function 
3 Modified Greene Climacteric Scale 
4Short Form-36 version 2 
5Patient Health Questionnaire–9 
6If a dual energy X-ray absorptiometry scan was performed within the last 3 months, it was 
not repeated 
7lipid profile/high sensitivity C-reactive protein/ C-terminal cross-linked telopeptide / 
procollagen type I N-terminal propeptide /inhibin B/anti-Mullerian hormone 
8follicle stimulating hormone, thyroid stimulating hormone, lipid profile 
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Figure 1 Treatment of Premature Ovarian Failure Trial flowchart  
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3.4 Dual energy X-ray absorptiometry scans  
Central skeleton (hip and lumbar spine) dual energy X-ray absorptiometry (DXA) measurements 
are considered to be the gold standard for measuring bone mineral density (BMD) and for 
monitoring changes in BMD following treatment (64).  The lumbar spine was chosen as the 
primary outcome for this study because it is the most sensitive to changes and considered the 
best site for monitoring changes with treatment (64, 140).  We recognise that degenerative 
changes in the lumbar spine can have an impact on bone density and could potentially progress 
over two years.  However, in this young population with a mean age of 40 we considered the 
risk of the progression of significant degenerative changes affecting the results to be minimal.  
Bone markers were not chosen as the primary outcome due to their high variability and lower 
evidence of relation to fractures than central BMD.   
Bone density at the lumbar spine (L1-4) and hip was measured by DXA scan (Hologic 
Discovery model) in the Osteoporosis Research Unit at Guy’s Hospital.  The scans were 
performed by a small number of radiographers, which minimises operator variations.  A DXA 
scan of the lumbar spine and hip takes approximately 10 minutes, including positioning.  The 
very low radiation dose of 8 microsieverts (0.008 mSv) is equivalent to approximately two days’ 
of everyday background radiation.   
The principle behind DXA scanning is the transmission of high and low energy photon X-rays 
through the body (141). The dual energy X-rays are produced by a fan beam DXA system which 
performs a single sweep across the patient over a few seconds.  The amounts of high and low 
energy X-rays transmitted are recorded and this enables the densities of two different types of 
tissue (bone and soft tissue) to be calculated.  The machines are calibrated each morning using 
phantom models, with a co-efficient of variation over the course of the study of 3.4% (see 
appendix F).  In vivo reproducibility is good, with a coefficient of variation for lumbar spine and 
total hip BMD of 1-1.5% (142). 
The T-score is calculated from the mean healthy young adult BMD and standard deviation, and 
the Z score from age, gender and ethnicity-specific BMD and standard deviation.  Data for this 
is derived from the Hologic database (for lumbar spine) and NHANES III data (for femoral neck 
and total hip).  In women under 50, Z rather than T scores should be used to interpret DXA 
results (143).  The Z scores for the local population at Guy’s Hospital are slightly higher than 
those from the US-derived data (+0.33 at the spine and +0.39 at the hip) but the US-derived 
data is still used to calculate them in order to enable comparisons to be made (144).   
3.5 Blood samples 
3.5.1 Acquisition 
Blood samples were taken from the antecubital fossa using a vacutainer system following an 
overnight fast of at least 14 hours.  One serum bottle was sent to the laboratory at Guy’s and St 
Thomas’ NHS Foundation Trust for analysis of high sensitivity C-reactive protein (hsCRP) and 
lipid profile.  Immediate analysis of the lipid profile is more accurate than analysis of previously 




chilled centrifuge at 3000 revs/minute for 10 minutes.  The samples were then separated and 
frozen in aliquots of 1ml for storage at -20°C (3 samples of serum for C-terminal cross-linked 
telopeptide / procollagen type I N-terminal propeptide /Inhibin B and one sample of plasma for 
anti-Mullerian hormone.  Frozen samples were transported on ice to St Thomas’ Hospital every 
three months for storage at -80°C until analysis by GSTS Pathology at the end of the trial. 
3.5.2   Analysis 
3.5.2.1 Markers of bone turnover 
3.5.2.1.1 procollagen type I N-terminal propeptide  
Serum procollagen type I N-terminal propeptide (P1NP) was measured by the Roche Elecsys 
total P1NP test.  This is an automated assay using anti-P1NP monoclonal antibodies to detect 
both trimeric and monomeric P1NP.  The sample is first incubated with biotintylated monoclonal 
P1NP-specific antibody.  It is then incubated with streptavadin labelled microparticles and a 
monoclonal P1NP-specific antibody labelled with a ruthenium complex.  These form a sandwich 
complex.  The mixture is put into a measuring cell and the microparticles are magnetically 
captured onto an electrode.  When a voltage is applied the chemiluminescent emission can be 
measured and plotted onto a calibration curve.  Serum P1NP is a stable when stored frozen and 
is unaffected by food intake (145).  
3.5.2.1.2   C-terminal cross-linked telopeptide  
Serum C-terminal cross-linked telopeptide (CTX) was measured by the Roche Elecsys β-
CrossLaps/serum assay, which is an automated assay using two specific monoclonal 
antibodies.  The principle of the assay is the same as the P1NP assay. It is also stable when 
frozen, but needs to be collected fasting, because changes over the period of the day are seen 
(146).   
3.5.2.2   Lipid profile 
The total cholesterol, high density lipoprotein (HDL) and triglyceride (TG) values were measured 
using enzymatic colimetric assays on a Roche automated clinical chemical analyser.  The 
principle of each assay is the same.  For total and HDL cholesterol measurement, enzymes are 
added to catalyse the reaction of cholesterol ester plus water to cholesterol plus fatty acid, and 
then the reaction of cholesterol plus oxygen to hydrogen peroxide.  Reagents are then added to 
produce a dye.  The intensity of this dye is directly proportional to the cholesterol’s 
concentration and is measured photometrically.  A similar technique was used to quantify 
triglycerides.  The reactions for each are detailed below. 
3.5.2.2.1 Total cholesterol 
 
  cholesterol esterase 
cholesterol esters + H2O                                                                              free cholesterol + fatty  






cholesterol oxidase  






H2O2 + reagents                                                                     red pigment + H2O 
 
3.5.2.2.2 High density lipoprotein 
 
PEG (polyethylene glycol) cholesterol esterase 
HDL-cholesterol esters + H2O                                                                     free HDL-cholesterol 
+fatty acids 
 
PEG cholesterol oxidase  
HDL-cholesterol + O2                                                                  H2O2 + Δ4cholestenone 
 
peroxidase 





triglycerides + H2O                                                                   glycerol + fatty acids 
 
     glycerokinase 
glycerol +ATP                                                                         glycerol-3phosphate+ 
ADP 
 
          glycerol phosphate dehydrogenase 








H2O2 + reagents                                                                     red pigment + H2O 
 
3.5.2.2.4 LDL 
LDL cholesterol was calculated using the Friedewald formula (147): 
LDL cholesterol (mmol/l) = total cholesterol – HDL cholesterol – (TG x 0.45) 
A baseline lipid profile requiring treatment was an exclusion criterion and therefore the 
conditions of using this formula were met in all participants. 
3.5.2.3 High sensitivity C-reactive protein  
High sensitivity C-reactive protein (hsCRP) was measured by particle enhanced 
immunoephelometry using BMTM Systems.  Serum is mixed with polystyrene particles coated 
with monoclonal antibodies specific to CRP, forming aggregates of polystyrene-CRP.  The 
density of these aggregates is measured by passing a beam of light through the sample; the 
intensity of the scattered light is proportional to the CRP concentration. 
3.5.2.4 Serum markers of ovarian reserve 
3.5.2.4.1  Anti-Mullerian hormone  
Anti-Mullerian hormone (AMH) was measured using the AMH Gen II ELISA (Beckman Coulter).  
This is an enzyme-linked immunosorbent assay (ELISA) using a 2-immunological step process.  
The sample is incubated in a microtitration well coated with AMH antibody.  Following 
incubation and washing, labelled anti-AMH detection antibody is added.  After a second 
incubation and washing, streptavidin-horseradish peroxidase is added and a third incubation 
and washing takes place.  An acidic stopping solution is then added and the degree of 
enzymatic turnover of the substrate is assessed by dual wavelength absorbance measurement.  
The sample’s AMH concentration is directly proportional to the absorbance.  AMH calibrators 
are used to plot a calibration curve enabling AMH concentrations to be calculated.   
This assay replaces the previously used AMH ELISA assays from Diagnostics Systems 
Laboratory and Immunotech, which gave different values for AMH measurement due to different 
standardisation.  The functional sensitivity of the AMH Gen II ELISA is 1.5 pmol/l (148).  AMH 
readings are approximately 40% higher than those obtained from the DSL ELISA assay.  A 
value of 6.4pmol/l has been identified as predicting poor response to IVF but there are no age-
related normative data as yet (148).   
3.5.2.4.2 Inhibin B 
Inhibin B was measured using the Inhibin B Gen II ELISA (enzyme-linked immunosorbent 
assay).  The principle is the same as that for measuring AMH.  The sample is incubated in 
microtitration wells containing anti-Activin B antibody.  After incubation and washing, the wells 
are incubated with biotinylated anti-Inhibin alpha-subunit detection antibody.  Following a 




horseradish peroxidase and the process is as for AMH but using a set of Inhibin B Gen II 
calibrators to plot the calibration curve so that Inhibin B can be calculated.    
3.6 Ultrasound markers of ovarian reserve 
The antral follicle count (AFC) and ovarian volume were assessed by trans-vaginal 2-
dimensional ultrasound using an 8.0 MHz probe.  Ultrasound uses the differential reflection of 
high frequency sound waves by different density tissues to create an image.  All ultrasound 
scans were performed by the research fellow using the same ultrasound machine (Siemens 
Sonoline Antares).  This avoided inter-observer variability.  I was trained to assess the AFC and 
ovarian volume by sonographers and clinicians in the Assisted Conception Unit at Guy;s 
Hospital, where these measurements are performed routinely in women undergoing fertility 
treatment.  Prior to starting the trial, I had 24 training sessions and scanned over 100 patients.  I 
was assessed as competent to locate the ovaries and measure ovarian volume and AFC by a 
senior sonographer.   
In premature ovarian failure it is relatively common to be unable to visualise one or both of the 
ovaries, due to their small size.  In a recent study where experienced fertility specialists 
assessed the AFC in women with POF, at least one of the ovaries was not visualised in 26% of 
the women (120). Where it was possible to visualise only one ovary, measurements of AFC and 
ovarian volume from that ovary were used in the analysis of the mean AFC/ovarian volume.   
3.6.1 Antral follicle count  
Following identification and magnification of the ovary, a transverse image was obtained and 
the probe moved very slowly from the superior to inferior aspect.  During this movement, all 
follicles measuring 2-10mm were counted.  Antral follicle count (AFC) assessment is widely 
used in reproductive medicine and the technique has been described previously (121, 123).  
Intra-observer variability in AFC assessment has been found to be small (149). The inter-
observer variability of AFC measurement is also favourable, and shows a trend towards better 
reproducibility at lower AFCs (149). It has been suggested that ultrasound AFC measurement is 
precise enough to be performed as a single measurement by a single observer (149). 
The AFCs for four participants were measured first by the research fellow then by a senior 
sonographer and the values compared.  In one of the participants, neither observer visualised 
the ovaries.  In another, neither could view the right ovary.  The remaining five ovaries were 
visualised by both observers and the correlation between their AFC assessments is shown 
below.  When the ovary was not visualised, the AFC was recorded as zero.  The correlation 







Figure 2 Correlation between antral follicle count measurements 
3.6.2 Ovarian volume 
The ovarian volume was calculated by obtaining a transverse and longitudinal view of the ovary.  
Three perpendicular diameters were used to calculate the volume in centimetres cubed. 
3.7 Questionnaires 
All questionnaires were completed at the start of the visit to avoid bias following interaction with 
the research fellow.  Short, self-administered questionnaires were chosen so that a wide range 
of relevant areas could be assessed.  
3.7.1 Modified Greene Climacteric Scale  
The Modified Greene Climacteric Scale (MGCS) (150) gives a brief, overall view of climacteric 
symptoms.  It contains 21 questions encompassing psychological, somatic, vasomotor 
symptoms, and there is a ‘probe question’ for sexual dysfunction.  The subject is asked to rate 
the severity of each symptom from none (0) to severe (3).  The scores are added to give an 
overall score, as well as scores for each aspect of the scale.  It was developed from factor-
analytic studies and was shown to be a reliable test for the assessment of somatic, vasomotor 
and psychological symptoms (test-retest reliability after 2 weeks 0.83-0.87).  Normative data for 
the general population and menopause clinic are available.  It has been recently demonstrated 
to continue to be a reliable measure of climacteric symptoms (151).  The scale has been widely 
used in clinical trials and Gynaecology clinics to assess the severity of climacteric symptoms 

























3.7.2 Menopause Symptoms Treatment Satisfaction Questionnaire     
The  Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) (154) contains 
eight questions and aims to assess satisfaction with a study medication over the last four 
weeks.  It is the only validated scale that assesses satisfaction with treatment aimed to alleviate 
menopausal symptoms.  For each question, the participant rates her satisfaction with the study 
medication from extremely dissatisfied (0) to extremely satisfied (4).  A percentage satisfaction 
score is then calculated.  If a single response is missing, the mean of the other responses can 
be used (154).  The threshold of satisfaction of control of hot flushes (calculated using the first 
two items on the questionnaire – satisfaction with control of hot flushes during day and night) – 
has been reported as a reduction of 1.6 hot flushes a day (155). 
3.7.3 Brief Profile of Female Sexual Function  
The Brief Profile of Female Sexual Function (B-PFSF) is a seven item questionnaire with a 
recall period of 2-3 months.  Its aim is to determine the presence of hypo-active sexual desire 
disorder (HSDD) in post-menopausal women (156).  For each item, the subject is asked to rate 
the frequency of occurrence from never (0) to always (5).  The score is added to give a total out 
of 35.  A score of 20 or below indicates HSDD (156). 
3.7.4 Patient Health Questionnaire-9  
The Patient Health Questionnaire-9 (PHQ-9) has nine questions, which are based on the nine 
criteria used to make the diagnosis of DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders IV) depressive disorder.  It aims to detect and assess the severity of depression over 
the last 2 weeks and can also assess response to treatment (157-159). It is widely used in 
primary care and reliability has been demonstrated in different ethnic groups (160).  
3.7.5 Short Form-36 version 2 (SF-36v2) 
The Short Form-36 version 2 (SF-36v2) Health Survey (161) aims to give an objective measure 
of health-related quality of life.  It is the most widely used quality of life tool in clinical trials.  
Normative data for many populations and age ranges are available.  It consists of thirty-six 
questions with graded responses and provides a 0-100 scale score for each domain.  Higher 
scores indicate better functioning, including in the bodily pain score, where a higher score 
indicates less limitation due to pain.  The SF-36 has a recall period of four weeks and provides 
scores in the following eight ‘health domain scales’: 
- Physical Functioning 
- Role-Physical 
- Bodily Pain 
- General Health 
- Vitality 





- Mental Health 
It provides summary scores for physical and mental health (physical component scale and 
mental component scale).  There is also one question on perceived health change over the last 
year.  Scoring is performed by software produced by Quality Metric.  The SF-36v2 has been 
used in one study in iatrogenic POF (56), in which a difference in the Summary of Physical 
Health score was found between the oestrogen therapy and untreated groups.     
3.8 Concordance with medication 
Concordance with medication was recorded at each visit as the number of pills left in each 
empty packet.  At the end of the study, the overall percentage of medication taken was 
calculated.  Independent markers of compliance were not performed but unscheduled bleeding 
was considered to be an adverse event and was enquired about at each visit.   
3.9 Calculation of sample size 
The initial target sample size was 90 (30 in each group). Assuming that the bone mineral 
density change within each group varies with a standard deviation of 4% (162, 163), a sample 
size of 22 in each group would be sufficient to detect a difference in the mean BMD change 
between groups of 4% assuming a 5% significance level and a power of 90%.  The aim was to 
recruit 30 women to each group in order to make adequate allowance for drop-outs. The 
following values were used to calculate this:  
Estimate of the standard deviation of bone mineral density change in each group: 4% 
Significance level: 5% 
Difference to be detected: 4% 
Power: 90% 
Required sample size: 22 in each group (calculated by statistician using Stata) 
3.10 Statistical methods 
Data were collected on paper Case Record Forms and then entered into a customised Excel 
spreadsheet.  Data entry was checked by Clinical Research Assistants from the King’s College 
London Joint Clinical Trials Office.  SPSS (Statistical Package for the Social Sciences) version 
19 was used for statistical analysis.  We obtained advice from a statistician (Paul Seed) on the 
best ways to analyse the data.  For baseline characteristics, independent sample t-tests were 
used to make comparisons between the treatment and no treatment groups when the variables 
were normally distributed, and the Mann-Whitney U test was used in cases of non-parametric 
distribution (demographics).  Baseline characteristics of the HRT and COCP groups were not 




For the results, all variables were tested for normality using histograms and Q-Q plots.  The 
majority of the variables were found to be normally distributed. For these variables, comparison 
of changes between the groups were performed using linear regression with adjustment for 
baseline values.  For bone density, comparisons with baseline values were made using paired t-
tests, because it is useful clinically to be able to advise a woman how much she can expect her 
bone density to go up (or down).   
The hsCRP and PHQ-9 data were not normally distributed and various transformations 
including log, inverse log, squaring and square rooting did not succeed in producing a normal 
distribution.  Statistical advice was sought, which was to use the non-parametric Mann-Whitney 
U test.   
Data have been illustrated graphically throughout as both all available data at each time-point 
and also absolute values for those who completed the trial.  This is because due to the high 
drop-out rate and small numbers, for some variables participants with complete data collection 
have noticeably different baseline values between groups.  It was felt appropriate to illustrate 






Chapter 4 Results 
4.1 Recruitment 
The majority of women were recruited through Guy’s and St Thomas’ NHS Foundation Trust 
(GSTFT) – either in the premature ovarian failure clinic or through referrals from colleagues.  A 
significant number were recruited having seen the advertisement on the Daisy Network website.  
An article on BBC online at the end of November 2010 which included contact details for the 
Menopause Research Unit led to over 200 enquiries, of which 7 women decided to participate in 
the study.  Table 4 summarises the routes of recruitment. 
 Number recruited 
GSTFT Premature Ovarian Failure clinic 25 
GSTFT Reproductive Medicine clinic 1 
Referred from colleague at GSTFT 6 
Referred from colleague at another hospital 1 
Daisy Network website 11 
British Menopause Society website 1 
GSTFT intranet and King’s College London 
circular e-mail 
5 
BBC online article 7 
Women’s Weekly Advert and Daily Express 
article 
2 













4.1.1 Recruitment rate 
The recruitment rate is shown in figure 3.  Recruitment was boosted following a press release in 
November 2010 which led to BBC online, Daily Express and Women’s Weekly articles.  The 
study was also featured on the front page of the hospital intranet. 
 
 



















































































































































4.2 Demographic data 
Tables 5 to 7 show the demographic characteristics of study participants in each group.   

















Ethnicity (%) White   64.4% 
Mixed   
Asian or Asian British 
Black or Black British 


























Unemployed   
































 8 (1, 10) 1 (0, 3) 2 (0, 10) 2 (0, 10) 









BMI (kg/m2)  24.7 
(3.6) 












Cardiovascular disease   
Hypertension    
Breast/ovarian/ 
endometrial/bowel 












































































































Under 45  


























for POF (%) 
 33 60 14 31 
Previous use 
of COCP for 
other 
reasons (%) 




































those with no 
partner) (%) 
 7 0 41 22 




4.3 Baseline symptoms 
Table 8 shows the baseline symptoms in each group. 
 HRT COCP No treatment All groups 
Hot flushes 60 73 38 52 
Night sweats 33 53 45 44 
Sleep 
disturbance  
67 53 45 53 
Change in mood 67 67 66 66 
Lack of energy   53 67 55 58 
Vaginal dryness 47 53 35 42 
Decreased libido  60 67 48 60 
Dyspareunia 27 33 25 23 
Palpitations 47 47 17 32 
Lack of 
concentration 
53 60 45 51 
Urinary problems  27 27 24 25 
Headache 47 33 35 37 
Skin itching 33 40 14 25 
Joint pain 47 53 38 44 
Depression 20 53 35 36 
Anxiety  47 40 41 42 
Irritability 60 60 55 58 
Low self esteem  33 47 31 36 
Other 33 20 17 22 
Table 8 Symptoms at baseline (%) 
Other symptoms included dry skin 3%, hair thinning 3%, fainting/dizziness 3%, leg cramps 2%, 





4.4 Screen failures 
Five women were not eligible for the trial following screening.  One had an initial FSH of below 
30IU/l and the other four had a second FSH value of below 30IU/l.  There were no other 
reasons for screen failure.  
4.5 Reasons behind choosing the treatment or no treatment group 
59 women were recruited to the study – 29 to the no treatment group and 30 to the treatment 
group.  The most common reason cited for declining treatment was a dislike of taking 
medication.  The main reason for choosing the treatment group was menopausal symptoms, 
followed by concerns about osteoporosis and cardiovascular disease.  Figures 4 and 5 show 
the main reasons women cited for their choices. 
 
Figure 4 Reasons for choosing no treatment.  ‘Other’ reasons included a mistrust of medication, 
themes of wanting to ‘stay natural’ or not put chemicals into the body and concerns over 


































Figure 5 Reasons for choosing treatment. ‘Other’ reasons included wanting to get hormones the 
body needs; feeling that body is lacking something; to keep tissues healthy; to treat symptoms 
of dry skin/fatigue; wanting to see if it makes any difference   
 
4.6 Baseline comparisons between the treatment and no treatment 
groups 
Independent sample t-tests were used to compare baseline characteristics between the 
treatment and no treatment groups when the variables were normally distributed, and the Mann-
Whitney U test was used in cases of non-parametric distribution (demographics).  p-values of 
<0.05 were seen between treatment and no treatment groups for Modified Greene Climacteric 
Scale (MGCS), Short Form-36 (SF-36) mental component score and Patient Health 
Questionnaire-9 (PHQ-9) score.  The treatment groups had a higher MGCS, indicating more 
menopausal symptoms, and had a higher depressions score (PHQ-9) and lower mental health 
summary score (SF-36), both indicating poorer mental health.  Baseline characteristics of the 











































 HRT COCP All treatment 
(HRT and 
COCP) 


















5 (2, 23) 21 (9, 32) 9 (4, 28) 11 (5, 28) 0.611 
Months since 
LMP 
11 (3, 25) 13 (5, 29) 12 (5, 25) 3 (1, 22) 0.063 
Blood pressure and BMI 
Systolic bp 
(mmHg) 
122 (11) 117 (8) 119 (10) 113 (14) 0.256 
Diastolic bp 
(mmHg) 
77 (11) 73 (13) 77 (12) 80 (12) 0.271 




22 (17) 24 (14) 23 (15) 16 (12) 0.037 








43 (14) 37 (16) 
 
40 (15) 47 (10) 0.040 
PHQ-9 score 9 (7) 10 (7) 9 (7) 6 (5) 0.028 
Bone mineral density and Z scores 







0.991 (0.141) 0.988 (0.119) 0.928 
Total hip Z-
score 
-0.1 (1.0) -0.5 (0.9) -0.28 (0.95) -0.155 (0.84) 0.596 






0.912 (0.136) 0.929 (0.098) 0.584 
Table 9 Baseline comparisons between treatment and no treatment groups. BMI body mass 
index, MGCS Modified Greene Climacteric Scale, SF-36 Short Form 36, BMD bone mineral 




4.7 Withdrawals from the study 
36 out of 59 women completed the study (61%).  The percentage completing follow up in each 
group was 52% in the no treatment group, 80% in the HRT group and 60% in the COCP group.  
The timing of drop-outs and reasons is shown in the flowchart. 
The most frequent reason for withdrawal was loss to follow up.  There was a slightly higher 
drop-out rate in the COCP group compared with the HRT group, but this was due to loss of 
follow up.  One participant in each of the treatment groups withdrew because she felt that the 
medication was contributing to symptoms of depression and she wanted to change medication.  
One participant in each treatment group withdrew due to side effects – in the COCP group this 
was breast tenderness and in the HRT group the participant reported that the medication was 
not helping, was making her symptoms worse, causing a headache and making her feel ‘not 
myself’.   One participant in the no treatment group withdrew for two reasons – a drop in bone 
















































































































9 completed study 
(60%) 
 
3 months n=26 
  
 
6 months n=13 
  
 
3 months n=14 
  
 
12 months n=13 
  
 
18 months n=12 
  
 
24 months n=12 
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0 months n=15 
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6 months n=24 
  
 
3 months n=14 
  
 
12 months n=22 
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18 months n=10 
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1 – menopausal 
symptoms 
1 – lost to FU 
 
 5 withdrawals 
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4.8 Compliance with medication 
Compliance with medication in the two treatment groups was calculated from the number of pills 
left in empty packets at the 6, 12, 18 and 24 month study visits.  On the few occasions when 
this was not recorded, the percentages from the visits where it was recorded are used.  For 
those who completed the trial, compliance was 95% in the COCP and 98% in the HRT group.  
Overall, compliance was 95% in the COCP and 98% in the HRT group.  We did not perform 
independent markers of compliance. 
4.9 Other medications taken during the study  
29 women took either prescribed or over the counter medication during the course of the study.  
Three women took antidepressants; one woman in the HRT group was already taking this at the 
start of the study and one woman in each of the other groups started an antidepressant during 
the study.  Three women took antihypertensives; one woman in the HRT group was already 
taking an antihypertensive at the start of the trial and one woman in each of the other groups 
started during the study.  Two women were already taking thyroxine at the start of the trial (one 
in the HRT and one in the COCP group) and continued on it throughout.  Eleven women took 
analgesia during the study.  Four women took medication for asthma – three in the HRT group 
were taking this at the start of the study and one woman in the no treatment group started 
during the study.  
Other medications taken were ferrous sulphate (two women), enoxaparin, a short course of 





4.10 Adverse events 
39 women in the study experienced at least one adverse event (17 in the no treatment group, 
11 in the HRT group and 11 in the COCP group).  There was one serious adverse event, which 
was a pregnancy in the no treatment group.  This resulted in the birth of a healthy baby.   
The most common adverse events are detailed in table 10 below. 
Column1 HRTHRT COCCOCP No treatment 
Breast tenderness 2 3 0 
Breast lump 1 0 1 
Pelvic pain/dysmenorrhoea 3 2 1 
Hot flushes /night sweats 4 2 6 
Headache/migraine 1 2 1 
Depression/feeling low 1 1 2 
Musculo-skeletal pain 0 2 3 
Pregnancy 0 0 1 
Nausea 0 1 0 
Infection (chest/upper 
respiratory tract/ear) 
1 1 3 
Urinary tract infection 1 1 0 
Chest pains 0 1 1 
Table 10 Numbers of most common adverse events by group  
In addition, in the no treatment group one woman had carpal tunnel syndrome which required 
decompression, one woman had anaemia which required investigation by endoscopy and there 
was one each of the following adverse events: dysuria, umbilical hernia, gastric reflux and fall. 
In the HRT group, one woman experienced patches of brown skin on her face, one had a 
simple ovarian cyst which required monitoring and one had an allergic skin reaction (which had 
happened to her previously when not on HRT).  Other adverse events in the HRT group were 
facial acne, worsening of menopausal symptoms, feeling edgy and nervous, longer periods and 
a fractured ankle due to trauma. 
In the COCP group, one woman experienced deterioration in eyesight and was under 
investigation for this by an ophthalmologist.  One woman had irregular vaginal spotting, one 




the COCP group were increased appetite and impaired glucose tolerance, each in a single 
participant. 
The breast lump and chest pains were investigated and found to be benign. 
4.11 Bone Mineral Density 
Comparisons with baseline values are shown in these results because it is useful clinically to be 
able to advise a patient how much bone loss can be anticipated in a given situation and how 
this may be affected by treatment.  Comparisons with baseline values are not used in the rest of 
the results because the main aim of the trial is to compare treatments.  Paired t-tests were used 
to compare results at 6, 12 and 24 months with baseline bone mineral density (BMD).   
At the lumbar spine, there was a significant gain in BMD with HRT at all time points, a drop in 
BMD in the no treatment group at 12 and 24 months and no change in BMD in the COCP 
group.  At the total hip, bone density was maintained in the HRT and COCP groups but did not 
increase over 24 months, whereas in the no treatment group there was a significant drop at all 
time points (figs 7 to 12).  At the femoral neck, there was a reduction in bone density in the no 
treatment group over the course of the trial, although this only became significant at 24 months.  
There were no significant changes compared with baseline values in the HRT or COCP groups.   
Comparison between the groups was performed using linear regression with adjustment for 
baseline bone mineral density.  This revealed a significant difference between the COCP and 
HRT groups in lumbar spine BMD at 12 and 24 months, in favour of HRT.  Fig 8 shows that 
women with complete data collection had comparable baseline values.  (This was not the case 
in some other results, particularly in the questionnaires.)  There were no differences between 
the COCP and HRT groups in change in total hip BMD.  At the femoral neck, there was a 
significant difference at 12 months in favour of HRT.   
Comparison between the HRT and no treatment groups of changes at both the lumbar spine 
and the hip were highly significant at all time-points in favour of HRT.  At the femoral neck the 
differences were significant at 12 and 24 months.   
Comparison of the COCP and no treatment groups at the lumbar spine revealed a trend in 
favour of COCP, but no statistically significant differences were found and a larger sample size 
would be needed to confirm any real difference.  However, the total hip results were similar to 
the HRT/no treatment comparison, with highly significant differences between the COCP and no 
treatment groups at all time-points in favour of COCP.  No significant differences were found 







4.11.1 Lumbar spine bone mineral density 


































% change from 
baseline to 6 
months 
 +2.45  +1.39  -0.37 
p value 6 months vs 
baseline BMD 
 0.005  0.145  0.476 
Change from 








% change from 
baseline to 12 
months 
 +3.83  +0.82  -1.09 
p value 12 months 
vs baseline BMD 
 <0.001  0.528  0.042 
Change from 








% change from 
baseline to 24 
months 
 +3.79  +0.29  -2.62 
p value 24 months 
vs baseline BMD 





Figure 7 Percent changes from baseline in mean lumbar spine bone mineral density (BMD) over 


















Figure 8 Changes in mean lumbar spine bone mineral density (BMD) (g/m2) over 24 months in 











4.11.1.1 Comparison between COCP and HRT 
Months COCP minus HRT  
mean lumbar spine 
BMD  
95% confidence 
interval of the 
difference  
p value 
6 -0.013 -0.034 to 0.008 0.216 
12 -0.032 -0.058 to -0.005 0.021 
24 -0.038 -0.073 to -0.002 0.040 
Table 12 Comparison between HRT and COCP lumbar spine bone mineral density (BMD) 
(g/m2) results.  Linear regression analysis was used to adjust for baseline score 
 
4.11.1.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean 
lumbar spine BMD  
95% confidence 
interval of the 
difference  
p value 
6 0.028 0.011 to 0.045 0.002 
12 0.049 0.031 to 0.068 <0.001 
24 0.065 0.038 to 0.093 <0.001 
Table 13 Comparison between HRT and no treatment lumbar spine bone mineral density (BMD) 
(g/m2) results.  Linear regression analysis was used to adjust for baseline score 
 
4.11.1.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean 
lumbar spine BMD  
95% confidence 
interval of the 
difference  
p value 
6 0.007 -0.001 to 0.016 0.099 
12 0.009 -0.001 to 0.019 0.091 
24 0.014  -0.001 to 0.028 0.066 
Table 14 Comparison between COCP and no treatment lumbar spine bone mineral density 






4.11.2 Total hip bone mineral density 
Table 15 Bone mineral density (BMD) results at the hip (g/m2) and comparisons with baseline 
 














Baseline total hip 
















% change from 
baseline to 6 months 
 +0.32  +1.41  -1.17 
p value 6 months vs 
baseline BMD 
 0.540  0.033  0.007 
Change from 








% change from 
baseline to 12 
months 
 +0.75  +0.71  -1.52 
p value 12 months 
vs baseline BMD 
 0.154  0.232  0.005 
Change from 








% change from 
baseline to 24 
months 
 +0.83  +0.33  -2.48 
p value 24 months 
vs baseline BMD 





Figure 9 Percent changes from baseline in mean total hip bone mineral density (BMD) over 24 







Figure 10 Changes in mean total hip bone mineral density (BMD) (g/m2) over 24 months in 






4.11.2.1 Comparison between HRT and COCP 
Months COCP minus HRT  
mean total hip BMD  
95% confidence 
interval of the 
difference  
p value 
6 0.008 -0.007 to 0.023 0.294 
12 0.000 -0.015 to 0.015 0.976 
24 -0.008 -0.027 to 0.012 0.431 
Table 16 Comparison between HRT and COCP total hip bone mineral density (BMD) (g/m2) 
results.  Linear regression analysis was used to adjust for baseline score 
 
4.11.2.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean total 
hip BMD  
95% confidence 
interval of the 
difference  
p value 
6 0.014 0.001 to 0.027 0.036 
12 0.020 0.007 to 0.034 0.004 
24 0.030 0.015 to 0.044 <0.001 
Table 17 Comparison between HRT and no treatment total hip bone mineral density (BMD) 
(g/m2) results.  Linear regression analysis was used to adjust for baseline score 
 
4.11.2.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean total 
hip BMD  
95% confidence 
interval of the 
difference  
p value 
6 0.011 0.004 to 0.018 0.002 
12 0.011 0.004 to 0.018 0.005 
24 0.012 0.004 to 0.020 0.005 
Table 18 Comparison between COCP and no treatment total hip bone mineral density (BMD) 






4.11.3 Femoral neck bone mineral density 
Table 19 Bone mineral density (BMD) results at the femoral neck (g/m2) and comparisons with 
baseline 
 






























% change from 
baseline to 6 
months 
 +1.59  +1.59  -0.24 
p value 6 months vs 
baseline BMD 
 0.069  0.243  0.644 
Change from 








% change from 
baseline to 12 
months 
 +1.66  -1.61  -0.91 
p value 12 months 
vs baseline BMD 
 0.161  0.071  0.175 
Change from 








% change from 
baseline to 24 
months 
 +1.16  +0.42  -1.78 
p value 24 months 
vs baseline BMD 





Figure 11 Percent changes from baseline in mean femoral neck bone mineral density (BMD) 













Figure 12 Changes in mean femoral neck bone mineral density (BMD) (g/m2) over 24 months in 











4.11.3.1 Comparison between COCP and HRT 
Months COCP minus HRT  
mean femoral neck 
BMD (g/m2) 
95% confidence 
interval of the 
difference (g/m2) 
p value 
6 0.000 -0.030 to 0.030 0.980 
12 -0.027 -0.052 to -0.002 0.033 
24 -0.009 -0.031 to 0.012 0.378 
Table 20 Comparison between HRT and COCP femoral neck bone mineral density (BMD) 
(g/m2) results.  Linear regression analysis was used to adjust for baseline score 
 
4.11.3.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean 
femoral neck BMD 
(g/m2) 
95% confidence 
interval of the 
difference (g/m2) 
p value 
6 0.015 -0.009 to 0.038 0.212 
12 0.020 0.001 to 0.040 0.043 
24 0.023 0.005 to 0.042 0.017 
Table 21 Comparison between HRT and no treatment femoral neck bone mineral density (BMD) 
(g/m2) results.  Linear regression analysis was used to adjust for baseline score 
 
4.11.3.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean 
femoral neck BMD 
(g/m2) 
95% confidence 
interval of the 
difference (g/m2) 
p value 
6 0.005 -0.009 to 0.019 0.474 
12 -0.003 -0.012 to 0.006 0.548 
24 0.008 -0.004 to 0.020 0.185 
Table 22 Comparison between COCP and no treatment femoral neck bone mineral density 




4.12 Bone turnover markers 
Both procollagen type I N-terminal propeptide (P1NP) and C-terminal cross-linked telopeptide 
(CTX) were reduced from baseline at all time points in the HRT and COCP groups.  The graphs 
show a trend towards a greater reduction in P1NP in the HRT group, but on statistical 
comparison there were no significant differences between the HRT and COCP groups on the 
extent of reduction of either CTX or P1NP.  In the no treatment group there was a slight 
increase in P1NP and CTX over the course of the trial.  When each treatment group was 
compared with the no treatment group, the differences were significant at every time-point for 
both CTX and P1NP.  The graphs showing women with complete data collection indicate that 
baseline values were very similar between the groups for both P1NP and CTX. 
4.12.1 Procollagen type I N-terminal propeptide  
Table 23 Procollagen type I N-terminal propeptide (P1NP) results (mcg/l) 
  


















































Figure 13 Percent changes from baseline in procollagen type I N-terminal propeptide (P1NP) 
results over 24 months showing all available data at each time-point.  Data shown as mean +/- 






Figure 14 Changes in mean procollagen type I N-terminal propeptide (P1NP) results (mcg/l) 







4.12.1.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean P1NP  
95% confidence 
interval of the 
difference  
p value 
6 3.5 -11.8 to 18.7 0.638 
12 7.2 -6.5 to 20.9 0.288 
24 5.8 -10.1 to 21.6 0.455 
Table 24 Comparison between HRT and COCP procollagen type I N-terminal propeptide 
(P1NP) results (mcg/l).  Linear regression analysis was used to adjust for baseline score 
4.12.1.2 Comparison between HRT and no treatment groups 




interval of the 
difference  
p value 
6 -29.4 -42.6 to -16.1 <0.001 
12 -30.4 -46.9 to -13.9 0.001 
24 -28.4  -42.3 to -14.5 <0.001 
Table 25 Comparison between HRT and no treatment procollagen type I N-terminal propeptide 
(P1NP) results (mcg/l).  Linear regression analysis was used to adjust for baseline score 
4.12.1.3 Comparison between COCP and no treatment groups 




interval of the 
difference  
p value 
6 -12.3 -18.8 to -5.9  <0.001 
12 -11.4 -21.7 to -1.0 0.032 
24 -11.0 -21.0 to -0.1 0.033 
Table 26 Comparison between COCP and no treatment procollagen type I N-terminal 







4.12.2   C-terminal cross-linked telopeptide  
Table 27 C-terminal cross-linked telopeptide (CTX) results (mcg/l) 
 
Figure 15 Percent changes from baseline in C-terminal cross-linked telopeptide (CTX) results 
over 24 months showing all available data at each time-point.  Data shown as mean +/- one 
standard error. 





























baseline to 12 
months 



















Figure 16 Changes in mean C-terminal cross-linked telopeptide (CTX) results (mcg/l) over 24 






4.12.2.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean CTX  
95% confidence 
interval of the 
difference  
p value 
6 0.03 -0.04 to 0.10 0.367 
12 0.02 -0.06 to 0.09 0.703 
24 0.05 -0.08 to 0.17 0.451 
Table 28 Comparison between HRT and COCP C-terminal cross-linked telopeptide (CTX) 
results (mcg/l).  Linear regression analysis was used to adjust for baseline score 
4.12.2.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean CTX  
95% confidence 
interval of the 
difference  
p value 
6 -0.18 -0.29 to -0.07 0.003 
12 -0.20 -0.30 to -0.11 <0.001 
24 -0.16 -0.25 to -0.07 0.001 
Table 29 Comparison between HRT and COCP C-terminal cross-linked telopeptide (CTX) 
results (mcg/l).  Linear regression analysis was used to adjust for baseline score 
4.12.2.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean CTX  
95% confidence 
interval of the 
difference  
p value 
6 -0.07 -0.13 to -0.02 0.006 
12 -0.10 -0.16 to -0.04 0.001 
24 -0.06 -0.12 to 0.00 0.046 
Table 30 Comparison between HRT and COCP C-terminal cross-linked telopeptide (CTX) 





4.13 Markers of ovarian function 
4.13.1 Anti-Mullerian Hormone and Inhibin B 
Anti-Mullerian hormone (AMH) was undetectable (less than 1.1 pmol/l) in all but one sample 
analysed.  The exception was a level of 3.0pmol/l at baseline in a participant in the no treatment 
group.  She withdrew following the 6 month visit, at which time her AMH was less than 
1.1pmol/l.  Her inhibin B levels were undetectable (<4.8 pg/ml) at baseline but increased to 255 
at 6 months.  Unfortunately the baseline samples for the participant in the no treatment group 
who became pregnant a few months into the trial were lost by the laboratory.   
Inhibin B was detectable in 17 participants on at least one occasion.  11 participants had a 
detectable level on more than one occasion.  This may represent a group of women with 
intermittent ovarian function, although in every case the AMH taken at the same time was 
undetectable.  The split between the groups was roughly proportionate to the numbers in each 

























Table 31 Inhibin B over 24 months in participants with at least one detectable level (pg/ml) 
 
4.13.2 Antral follicle count and ovarian volume 
Due to unforeseeable circumstances the ultrasound machine became unavailable at the end of 
January 2010.  The machine that replaced it was inadequate for accurately locating the ovaries 
and measuring the antral follicle count.  This meant that baseline data was collected only on the 
first 29 participants.  Six month data was collected from only 5 participants and therefore has 
group study 
number 








6 14.3 undetectable withdrew withdrew 
17 17.1 undetectable undetectable undetectable 
22 31.9 16.5 27.1 undetectable 
26 undetectable 255.0 withdrew withdrew 
27 undetectable undetectable 22.6 undetectable 
28 undetectable 21.1 80.9 undetectable 
34 40.7 18.1 undetectable undetectable 
36 5.4 no sample undetectable 24.2 




32 10.5 48.9 undetectable undetectable 
45 45.2 undetectable undetectable undetectable 
54 53.3 undetectable undetectable undetectable 




29 24.1 withdrew withdrew withdrew 
41 undetectable 55.2 no sample undetectable 
49 undetectable 51.4 64.2 undetectable 




not been analysed.  Baseline data is presented below.  As expected in this population, data is 
skewed to the left and is therefore presented as median (25, 75%). 
 Median (25, 75%) 
Antral follicle count 5.0 (3.0, 7.8) 
Ovarian volume (cm3) 2.5 (1.3, 5.1) 
Endometrial thickness (mm) 2.8 (2.0, 4.8) 





Several of the lipid profile parameters show trends in favour of HRT (for example, a reduction in 
low density lipoprotein in the HRT group, and a reduction in high density lipoprotein in the 
COCP group), but on formal statistical analysis few significant differences were found.  A larger 
sample size would be needed to confirm a true difference. 
4.13.3 Low density lipoprotein 
Figs 17 and 18 appear to show a reduction in low density lipoprotein (LDL) in the HRT group at 
6 months which is then maintained over the course of the trial, whereas the levels in the COCP 
and no treatment groups remain relatively constant.  However, statistical analysis did not reveal 









Figure 17 Percent changes from baseline in mean low density lipoprotein (LDL) over 24 months 
showing all available data at each time-point.  Data shown as mean +/- 1 standard error. 
 

















































Figure 18 Changes in mean low density lipoprotein (LDL) (mmol/l) over 24 months in 






4.13.3.1 Comparison between HRT and COCP 
Months COCP minus HRT 
mean LDL  
95% confidence 
interval of the 
difference  
p value 
6 0.08 -0.30 to 0.47 0.657 
12 0.24 -0.19 to 0.67 0.252 
24 0.05 -0.51 to 0.62 0.843 
Table 34 Comparison between HRT and COCP low density lipoprotein (LDL) results (mmol/l).  
Linear regression analysis was used to adjust for baseline score 
 
4.13.3.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean LDL  
95% confidence 
interval of the 
difference  
p value 
6 -0.17 -0.53 to 0.18 0.329 
12 0.16 -0.18 to 0.49 0.341 
24 0.02 -0.40 to 0.43 0.928 
Table 35 Comparison between HRT and no treatment low density lipoprotein (LDL) results 
(mmol/l).  Linear regression analysis was used to adjust for baseline score 
 
4.13.3.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean LDL  
95% confidence 
interval of the 
difference  
p value 
6 -0.03 -0.19 to 0.12 0.658 
12 0.14 0.01 to 0.28 0.037 
24 0.06 -0.14 to 0.26 0.532 
Table 36 Comparison between COCP and no treatment low density lipoprotein (LDL) results 





4.13.4 High density lipoprotein 
A reduction in high density lipoprotein (HDL) was seen in the COCP group from 6 months, 
whilst levels in the HRT and no treatment groups remained relatively stable.  The differences 
between the COCP and HRT groups at 6 and 12 months were significant (p 0.001 and 0.030), 
but at 24 months the significance level was 0.091.  Comparison between the HRT and no 
treatment groups did not reveal any statistically significant differences.  There were highly 
significant differences between the COCP and no treatment groups at 6 and 12 months, and the 
difference remained significant at 24 months (p 0.049). 
Table 37 High density lipoprotein (HDL) results (mmol/l) 
  

















































Figure 19 Percent changes from baseline in mean high density lipoprotein (HDL) over 24 







Figure 20 Changes in mean high density lipoprotein (HDL) (mmol/l) over 24 months in 
participants with complete data collection 
 
4.13.4.1 Comparison between HRT and COCP 
Months COCP minus HRT 
mean HDL  
95% confidence 
interval of the 
difference 
p value 
6 -0.27 -0.42 to -0.13 0.001 
12 -0.22 -0.41 to -0.02 0.030 
24 -0.19 -0.41 to 0.03 0.091 
Table 38 Comparison between HRT and COCP high density lipoprotein (HDL) results (mmol/l).  




4.13.4.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean HDL  
95% confidence 
interval of the 
difference  
p value 
6 -0.11 -0.31 to 0.09 0.252 
12 -0.19 -0.39 to 0.00 0.054 
24 -0.03 -0.24 to 0.18 0.765 
Table 39 Comparison between HRT and no treatment high density lipoprotein (HDL) results 
(mmol/l).  Linear regression analysis was used to adjust for baseline score 
 
4.13.4.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean HDL  
95% confidence 
interval of the 
difference  
p value 
6 -0.19 -0.29 to -0.09 0.001 
12 -0.21 -0.31 to -0.12 <0.001 
24 -0.11 -0.22 to -0.00 0.049 
Table 40 Comparison between COCP and no treatment high density lipoprotein (HDL) results 






4.13.5 Total cholesterol 
Figs 21 and 22 show a similar reduction in total cholesterol in both the HRT and COCP groups 
from 6 months, whereas in the no treatment group levels remain constant.  However, there were 
no consistently significant differences between the groups. 
Table 41 Total cholesterol results (mmol/l) 
 
 


















































Figure 21 Percent changes from baseline in total cholesterol over 24 months showing all 






Figure 22 Changes in mean total cholesterol (mmol/l) over 24 months in participants with 
complete data collection 
 
4.13.5.1 Comparison between HRT and COCP 
Months COCP minus HRT 
mean total cholesterol  
95% confidence 
interval of the 
difference  
p value 
6 -0.14 -0.56 to 0.27 0.479 
12 0.00 -0.47 to 0.48 0.993 
24 -0.05 -0.70 to 0.60 0.874 
Table 42 Comparison between HRT and COCP total cholesterol results (mmol/l).  Linear 





4.13.5.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean total 
cholesterol  
95% confidence 
interval of the 
difference  
p value 
6 -0.28 -0.68 to 0.11 0.156 
12 0.02 -0.35 to 0.38 0.933 
24 -0.07 -0.54 to 0.40 0.765 
Table 43 Comparison between HRT and no treatment total cholesterol results (mmol/l).  Linear 
regression analysis was used to adjust for baseline score 
 
4.13.5.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean total 
cholesterol  
95% confidence 
interval of the 
difference  
p value 
6 -0.22 -0.39 to -0.04 0.019 
12 -0.04 -0.21 to 0.13 0.611 
24 -0.05 -0.30 to 0.20 0.667 
Table 44 Comparison between COCP and no treatment total cholesterol results (mmol/l).  







Figs 23 and 24 indicate that triglycerides decreased in all groups, but most in the no treatment 
group.  There were no significant differences between the groups.   
Table 45 Triglyceride results (mmol/l) 
  

















































Figure 23 Percent changes from baseline in triglycerides over 24 months showing all available 





Figure 24 Changes in mean triglycerides (mmol/l) over 24 months in participants with complete 
data collection 
 
4.13.6.1 Comparison between HRT and COCP 
Months COCP minus HRT 
mean triglycerides  
95% confidence 
interval of the 
difference  
p value 
6 -0.00 -0.25 to 0.24 0.987 
12 0.04 -0.14 to 0.22 0.625 
24 0.03 -0.32 to 0.39 0.842 
Table 46 Comparison between HRT and COCP triglycerides results (mmol/l).  Linear regression 





4.13.6.2 Comparison between HRT and no treatment 




interval of the 
difference  
p value 
6 0.06 -0.17 to 0.29 0.593 
12 0.03 -0.15 to 0.20 0.754 
24 0.05 -0.18 to 0.29 0.642 
Table 47 Comparison between HRT and no treatment triglycerides results (mmol/l).  Linear 
regression analysis was used to adjust for baseline score 
 
4.13.6.3 Comparison between COCP and no treatment 




interval of the 
difference  
p value 
6 0.03  -0.07 to 0.13 0.536 
12 0.04 -0.08 to 0.15 0.523 
24 0.04 -0.07 to 0.15 0.450 
Table 48 Comparison between COCP and no treatment triglycerides results (mmol/l).  Linear 







4.14 High Sensitivity C-Reactive Protein 
The high sensitivity C-reactive protein (hsCRP) results were not normally distributed and 
therefore data are shown as median (25, 75%).  Attempts to transform the data into a normal 
distribution, including using logs, inverse, squaring and square roots were not successful in 
achieving a normal distribution.  Following statistical advice, the non-parametric Mann Whitney-
U test was used to compare changes between groups.  One woman in the no treatment group 
had a very high hsCRP due to sarcoidosis and arthritis and her results were excluded prior to 
analysis.  Problems with analysis in the laboratory meant that there were more missing data in 
the hsCRP results than elsewhere.   
Fig 25 shows that the hsCRP increased at all time-points in the COCP group but remained 
relatively unchanged in the HRT and no treatment groups.  The differences between the groups 
were significant at all time-points when comparing the COCP and no treatment groups, and at 
24 months between the COCP and HRT groups.  However, these results need to be interpreted 
with caution for two reasons.  Firstly, the numbers are very small, especially at 24 months in the 
COCP group.  Secondly, the COCP group had a lower hsCRP than the other groups at baseline 
and this was even more marked amongst women who completed the trial, as shown in fig 26.  
Various transformations of the data did not produce a normal distribution and therefore it was 
not possible to use linear regression for analysis.  It is not possible to control for the baseline 
score with non-parametric tests.  
 
Table 49 High sensitivity C-reactive protein (hsCRP) results (mg/l) 
 
  
































































Figure 25 Changes from baseline in high sensitivity C-reactive protein (hsCRP) (mg/l) median 





Figure 26 Changes from baseline in high sensitivity C-reactive protein median score (hsCRP) 
(mg/l) in participants with complete data collection 
4.14.1 Comparison between groups 
Mann-Whitney U tests showed a significant difference between the changes in score in the HRT 
and COCP groups at 24 months, but not at 6 or 12 months (p values 0.078, 0.307 and 0.035 at 
6, 12 and 24 months respectively).  There were no significant differences between the changes 
in the HRT and no treatment groups (p values 0.352, 0.869 and 0.622 at 6, 12 and 24 months).  
However, comparison between the COCP and no treatment groups revealed significant 







4.15 Modified Greene Climacteric Scale 
The Modified Greene Climacteric Scale (MGCS) results between HRT and COCP groups are 
difficult to interpret because although the scores were similar at baseline (as expected following 
randomisation), the women who completed the trial in the COCP group had higher baseline 
scores than women who completed the trial in the HRT group (see figure 28 below).  The higher 
drop-out rate in the COCP group was due to loss of follow up, and there were just two reported 
withdrawals in the treatment groups due to menopausal symptoms - one each in the HRT and 
COCP groups.  However, it is possible that loss of follow up in either group could have been 
due to problems with symptom control.  Due to differences in baseline scores between 
participants who completed the trial and those who dropped out, graphs illustrating both all data 
collected and those with complete data collection are shown here and for the other 
questionnaires. 
At 3 and 6 months there are good amounts of data from both the COCP and HRT groups.  The 
results at 3 months include data from 14/15 participants in the HRT group and 13/15 in the 
COCP group.  At this time point, the reductions in the total, psychological, anxiety, somatic and 
vasomotor scores are statistically significantly greater in the HRT group.  However, at 6 months, 
with data available in 13/15 in the HRT group and 12/15 in the COCP group, there are no 
significant differences in scores.  It appears that the COCP takes longer to control symptoms 
but by 6 months the results are comparable.  This is supported by the graphs that present data 
from women who completed the trial and attended all visits (fig 28, 30, 32, 24 and 36); in these 
women a sharp reduction in score is seen in the HRT group at 3 months and the score then 
stabilises, whereas in the COCP group the reduction in score continues from 3 to 6 months.  
This is seen in each domain except vasomotor and sexual dysfunctions scores.  In the 
vasomotor score, HRT and the COCP follow a similar pattern of rapid symptom reduction at 3 
months then stabilisation of score.  Scores are similar in each domain except somatic at 12 
months.  However, by 24 months there are significant differences between the HRT and COCP 
groups in all scores except sexual dysfunction and vasomotor scores.  All differences are in 
favour of HRT.  There are no significant differences between the HRT and COCP groups at any 
time-point in the sexual dysfunction score.   
The regression analyses comparing the groups control for baseline score, and therefore 
estimates of differences between the groups are markedly different from the changes from 
baseline shown in the tables. 
In the no treatment group, there was a high drop-out rate and several of these were due to 
menopausal symptoms.  Therefore the results from this group should be interpreted as what 
happens to women who choose to continue on no treatment.  It should also be noted that the no 
treatment group had significantly lower scores at baseline.  The no treatment group was not 
randomised and therefore comparisons with the treatment groups are less valuable than 
comparisons between the two treatment groups.  However, they illustrate the large differences 
between the HRT and no treatment groups and the few differences between the COCP and no 




reductions in score in the HRT group at almost all time-points and in all domains except sexual 
function.  In contrast, the COCP versus no treatment comparison did not show a significant 
difference in total, psychological, anxiety, depression or somatic score at any time-point.  There 
was a trend towards reduction in vasomotor symptoms in the COCP group compared with no 
treatment, but this only reached a significance level of less than 0.05 at 6 and 12 months.  This 
contrasts sharply with the results in the HRT versus no treatment vasomotor score 
comparisons. 
 
4.15.1 Total score 
Table 50 Modified Greene Climacteric Scale (MGCS) total score results 
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Figure 27 Changes from baseline in total Modified Greene Climacteric Scale (MGCS) mean 







Figure 28 Changes in total Modified Greene Climacteric Scale (MGCS) over 24 months in 
participants with complete data collection 
4.15.1.1 Comparison between HRT and COCP 
Months COCP minus HRT 
mean total MGCS 
results 
95% confidence 
interval of the 
difference 
p value 
3 9.5 3.7 to 15.2 0.002 
6 4.0 -2.4 to 10.3 0.205 
12 7.5 -0.4 to 15.4 0.062 
18 9.6 1.8 to 17.5 0.018 
24 10.4 3.7 to 17.0 0.004 
Table 51 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 




4.15.1.2 Comparison between HRT and no treatment 
Months HRT minus no 
treatment mean total 
MGCS results 
95% confidence 
interval of the 
difference 
p value 
3 -7.9 -11.8 to -4.0 <0.001 
6 -5.7 -10.0 to -1.4 0.011 
12 -8.6 -14.4 to -2.7 0.005 
18 -9.1 -14.1 to -4.1 0.001 
24 -8.6 -14.8 to -2.6 0.007 
Table 52 Comparison between HRT and no treatment total Modified Greene Climacteric Scale 
(MGCS) score results.  Linear regression analysis was used to adjust for baseline score. 
 
4.15.1.3 Comparison between COCP and no treatment 
Months COCP minus no 
treatment mean total 
MGCS results 
95% confidence 
interval of the 
difference 
p value 
3 0.4 -2.0 to 2.7 0.759 
6 -1.4 -4.0 to 1.2 0.285 
12 -1.2 -5.1 to 2.8 0.552 
18 -1.1 -4.8 to 2.7 0.569 
24 -0.6 -4.2 to 3.0 0.715 
Table 53 Comparison between COCP and no treatment total Modified Greene Climacteric Scale 






4.15.2 Psychological score 
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Figure 29 Changes from baseline in Modified Greene Climacteric Scale (MGCS) psychological 






Figure 30 Changes in Modified Greene Climacteric Scale (MGCS) psychological score over 24 
months in participants with complete data collection 
4.15.2.1 Comparison between HRT and COCP groups 




interval of the 
difference 
p value 
3 5.9 2.4 to 9.3 0.002 
6 3.0 -0.8 to 6.8 0.116 
12 4.0 -0.4 to 8.4 0.071 
18 5.1 0.9 to 9.4 0.021 
24 5.2 1.1 to 9.3 0.015 
Table 55 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 




Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 -3.6 -6.5 to -0.8 0.013 
6 -2.9 -5.7 to -0.1 0.041 
12 -5.5 -8.7 to -2.2 0.002 
18 -5.7 -8.8 to -2.6 0.001 
24 -5.1 -9.0 to -1.2 0.012 
Table 56 Comparison between HRT and no treatment Modified Greene Climacteric Scale 
(MGCS) psychological score results.  Linear regression analysis was used to adjust for baseline 
score. 
 
4.15.2.2 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 1.0 -0.5 to 2.4 0.186 
6 -0.3 -2.0 to 1.4 0.725 
12 -1.2 -3.3 to 0.8 0.220 
18 -0.7 -2.8 to 1.3 0.467 
24 -0.5 -2.8 to 1.7 0.637 
Table 57 Comparison between COCP and no treatment Modified Greene Climacteric Scale 







4.15.3 Anxiety score 
Table 58 Modified Greene Climacteric Scale (MGCS) anxiety score results 
 





































































Figure 31 Changes from baseline in Modified Greene Climacteric Scale (MGCS) anxiety mean 






Figure 32 Changes in Modified Greene Climacteric Scale (MGCS) anxiety score over 24 months 
in participants with complete data collection 
4.15.3.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean MGCS anxiety 
results 
95% confidence 
interval of the 
difference 
p value 
3 3.8 2.0 to 5.5 <0.001 
6 1.4 -0.6 to 3.5 0.167 
12 2.1 -0.1 to 4.4 0.064 
18 2.3 0.0 to 4.6 0.052 
24 2.7 0.2 to 5.2 0.038 
Table 59 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 




4.15.3.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean 
MGCS anxiety results 
95% confidence 
interval of the 
difference 
p value 
3 -2.5 -4.0 to -1.0 0.002 
6 -1.4 -2.8 to 0.0 0.056 
12 -2.7 -4.7 to -0.6 0.011 
18 -2.6 -4.5 to -0.7 0.009 
24 -2.6 -4.9 to -0.3 0.031 
Table 60 Comparison between HRT and no treatment Modified Greene Climacteric Scale 
(MGCS) anxiety score results.  Linear regression analysis was used to adjust for baseline score. 
 
4.15.3.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean 
MGCS anxiety results 
95% confidence 
interval of the 
difference 
p value 
3 0.5 -0.4 to 1.3 0.273 
6 -0.0 -1.0 to 0.9 0.923 
12 -0.5 -1.8 to 0.8 0.465 
18 -0.4 -1.5 to 0.8 0.540 
24 -0.3 -1.7 to 1.1 0.630 
Table 61 Comparison between COCP and no treatment Modified Greene Climacteric Scale 






4.15.4 Depression score 
Table 62 Modified Greene Climacteric Scale (MGCS) depression score results 
 








































































Figure 33 Changes from baseline in Modified Greene Climacteric Scale (MGCS) depression 






Figure 34 Changes in Modified Greene Climacteric Scale (MGCS) depression score over 24 
months in participants with complete data collection 
4.15.4.1 Comparison between HRT and COCP groups 




interval of the 
difference 
p value 
3 2.1 -0.06 to 4.2 0.056 
6 1.6 -0.5 to 3.8 0.133 
12 1.7 -0.7 to 4.1 0.149 
18 2.8 0.4 to 5.2 0.027 
24 2.6 0.5 to 4.7 0.017 
Table 63 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 




4.15.4.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 -1.1 -2.7 to 0.5 0.177 
6 -1.6 -3.2 to 0.1 0.064 
12 -2.6 -4.3 to -1.0 0.002 
18 -3.9 -7.0 to -0.8 0.017 
24 -2.7 -4.6 to -0.8 0.008 
Table 64 Comparison between HRT and no treatment Modified Greene Climacteric Scale 
(MGCS) depression score results.  Linear regression analysis was used to adjust for baseline 
score. 
 
4.15.4.3 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 0.5 -0.3 to 1.3 0.240 
6 -0.1 -1.0 to 1.7 0.755 
12 -0.5 -1.4 to 0.3 0.216 
18 -1.2 -3.0 to 0.5 0.157 
24 -0.2 -1.4 to 0.9 0.667 
Table 65 Comparison between COCP and no treatment Modified Greene Climacteric Scale 








4.15.5 Somatic score 
Table 66 Modified Greene Climacteric Scale (MGCS) somatic score results 
 
 





































































Figure 35 Changes from baseline in Modified Greene Climacteric Scale (MGCS) somatic mean 






Figure 36 Changes in Modified Greene Climacteric Scale (MGCS) mean somatic score over 24 
months in participants with complete data collection 
4.15.5.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean MGCS somatic 
results 
95% confidence 
interval of the 
difference 
p value 
3 3.0 0.9 to 5.0 0.006 
6 1.2 -0.5 to 2.9 0.172 
12 2.4 0.2 to 4.6 0.034 
18 3.4 1.0 to 5.9 0.008 
24 3.8 2.3 to 5.4 <0.001 
Table 67 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 




4.15.5.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 -2.0 -3.3 to -0.7 0.003 
6 -0.9 -2.5 to 0.7 0.249 
12 -1.8 -3.4 to -0.1 0.034 
18 -1.0 -2.4 to 0.4 0.152 
24 -1.9 -3.6 to -0.2 0.031 
Table 68 Comparison between HRT and no treatment Modified Greene Climacteric Scale 
(MGCS) somatic score results.  Linear regression analysis was used to adjust for baseline 
score. 
 
4.15.5.3 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 0.3 -0.5 to 1.2 0.425 
6 0.2 -0.7 to 1.0 0.705 
12 0.2 -0.9 to 1.3 0.687 
18 0.9 -0.4 to 2.1 0.155 
24 0.6 -0.4 to 1.6 0.246 
Table 69 Comparison between COCP and no treatment Modified Greene Climacteric Scale 








4.15.6 Vasomotor score 
Table 70 Modified Greene Climacteric Scale (MGCS) vasomotor score results 
 




































































Figure 37 Changes from baseline in Modified Greene Climacteric Scale (MGCS) vasomotor 






Figure 38 Changes in Modified Greene Climacteric Scale (MGCS) mean vasomotor score over 
24 months in participants with complete data collection 
4.15.6.1 Comparison between HRT and COCP groups 




interval of the 
difference 
p value 
3 1.1 0.0 to 2.1 0.048 
6 0.4 -0.9 to 1.7 0.558 
12 0.9 -0.5 to 2.3 0.209 
18 1.0 -0.7 to 2.7 0.240 
24 1.1 -0.2 to 2.5 0.094 
Table 71 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 




4.15.6.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 -1.9 -2.9 to -0.9 <0.001 
6 -1.6 -2.6 to -0.5 0.004 
12 -1.9 -2.8 to -1.0 <0.001 
18 -1.6 -2.7 to -0.6 0.005 
24 -1.2 -2.5 to 0.1 0.068 
Table 72 Comparison between HRT and no treatment Modified Greene Climacteric Scale 
(MGCS) vasomotor score results.  Linear regression analysis was used to adjust for baseline 
score. 
 
4.15.6.3 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 -0.6 -1.3 to 0.0 0.061 
6 -0.8 -1.5 to -0.0 0.039 
12 -0.8 -1.5 to -0.1 0.033 
18 -0.5 -1.4 to 0.2 0.189 
24 -0.2 -1.2 to 0.7 0.623 
Table 73 Comparison between COCP and no treatment Modified Greene Climacteric Scale 







4.15.7 Sexual Dysfunction score 











































































Figure 39 Changes from baseline in Modified Greene Climacteric Scale (MGCS) sexual 






Figure 40 Changes in Modified Greene Climacteric Scale (MGCS) mean sexual dysfunction 
score over 24 months in participants with complete data collection 
4.15.7.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean MGCS sexual 
dysfunction results 
95% confidence 
interval of the 
difference 
p value 
3 -0.1 -0.7 to 0.5 0.673 
6 0.0 -0.7 to 0.7 0.990 
12 0.6 -0.3 to 1.4 0.213 
18 0.2 -0.9 to 1.3 0.665 
24 0.1 -0.8 to 1.1 0.752 
Table 75 Comparison between HRT and COCP Modified Greene Climacteric Scale (MGCS) 





4.15.7.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 -0.4 -0.9 to 0.1 0.103 
6 -0.3 -0.9 to 0.2 0.220 
12 -0.6 -1.2 to -0.0 0.049 
18 -0.3 -0.9 to 0.4 0.436 
24 -0.5 -1.1 to 0.2 0.147 
Table 76 Comparison between HRT and no treatment Modified Greene Climacteric Scale 
(MGCS) sexual dysfunction score results.  Linear regression analysis was used to adjust for 
baseline score. 
 
4.15.7.3 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 -0.3 -0.5 to -0.0 0.024 
6 -0.1 -0.4 to 0.2 0.373 
12 -0.0 -0.4 to 0.4 0.912 
18 0.0 -0.4 to 0.4 0.974 
24 -0.2 -0.7 to 0.2 0.234 
Table 77 Comparison between COCP and no treatment Modified Greene Climacteric Scale 







4.16 Menopause Symptoms Treatment Satisfaction Questionnaire  
The Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) was completed by 
women in the HRT and COCP groups at 3, 6, 12, 18 and 24 months.  There is no baseline 
score, because it assesses satisfaction with treatment.  The results therefore need to be 
interpreted with caution because of the high drop-out rate, especially in the COCP group, and 
because we know from the Modified Greene Climacteric Scale results that the women who 
completed the trial in the COCP group had higher baseline symptom scores than those who 
completed the trial in the HRT group.   
Comparison between the groups revealed a significant difference at 3 months (p=0.003) in 
favour of HRT.  This was not seen at 6 months, which fits with other questionnaires used in this 
trial (Modified Greene Climacteric Score, Patient Health Questionnaire-9) in which the COCP 
group took longer to experience symptom reduction.  At 12 months satisfaction with the COCP 
dropped and the difference between HRT and COCP is again significant in favour of HRT 
(p=0.040) but this reduces at 18 and 24 months, possibly because of a decreasing number of 










Table 78 Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) results 
 
 
 HRT COCP 
































Figure 41 Mean Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) score 






Figure 42 Mean Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) score 
over 24 months showing all available data at each time-point 
 
4.16.1 Comparison between groups 
Months COCP minus HRT 
mean MS-TSQ score 
95% confidence 
interval of the 
difference 
p value 
3 -16.4 -26.7 to -6.1 0.003 
6 -5.7 -22.0 to +10.7 0.480 
12 -19.1 -37.3 to -0.98 0.040 
18 -12.6 -26.2 to +0.9 0.066 
24 -8.5 -23.8 to +6.8 0.260 
Table 79 Comparison between HRT and COCP Menopause Symptoms Treatment Satisfaction 
Questionnaire (MS-TSQ) score results.  Independent sample t-tests were used to compare 




4.17 Brief Profile of Female Sexual Function 
There were more missing data from this questionnaire than the others due to some women not 
feeling able to complete the questionnaire, largely due to not being sexually active.  Fig 43 
shows that the Brief Profile of Female Sexual Function (BPFSF) scores in the no treatment and 
COCP groups remained relatively unchanged throughout the trial, whereas in the HRT group an 
increase was seen from 3 months and was maintained at a similar level over the duration of the 
trial.  Fig 44, which illustrates the scores from subjects with complete data collection, shows that 
from almost identical baseline scores in the HRT and COCP groups, the score in the HRT group 
increased at 3 months and then remained relatively stable for the duration of the trial.  However, 
when the HRT and COCP groups were compared formally, although there was a trend in favour 
of HRT increasing the BPFSF score to a greater extent, the differences did not reach a 
significance level of <0.05.  Comparison between HRT and no treatment revealed significant 
differences at most time-points; a reduction in significance level at 24 months was likely due to 
decreased numbers.  In contrast, there were no significant differences between the COCP and 
no treatment groups.   
Table 80 Brief Profile of Female Sexual Function (BPFSF) results 




































































Figure 43 Changes from baseline in Brief Profile of Female Sexual Function (BPFSF) mean 





Figure 44 Changes in mean Brief Profile of Female Sexual Function (BPFSF) score over 24 
months in participants with complete data collection 
4.17.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean BPFSF score 
95% confidence 
interval of the 
difference 
p value 
3 -4.1 -9.0 to 0.8 0.097 
6 -3.9 -8.3 to 0.5 0.081 
12 -4.4 -9.3 to 0.5 0.074 
18 -4.3 -10.9 to 2.4 0.193 
24 -4.7 -12.0 to 2.7 0.195 
Table 81 Comparison between HRT and COCP Brief Profile of Female Sexual Function 




4.17.2 Comparison between HRT and no treatment groups 




interval of the 
difference 
p value 
3 4.1 0.3 to 7.9 0.036 
6 4.3 -0.2 to 8.8 0.060 
12 4.4 0.4 to 8.3 0.032 
18 4.5 0.1 to 8.8 0.045 
24 2.8 -2.1 to 7.7 0.254 
Table 82 Comparison between HRT and no treatment Brief Profile of Female Sexual Function 
(BPFSF) score results.  Linear regression analysis was used to adjust for baseline score 
 
4.17.3 Comparison between COCP and no treatment groups 




interval of the 
difference 
p value 
3 -0.2 -2.2 to 1.8 0.860 
6 -0.1 -2.2 to 2.0 0.900 
12 -0.2 -2.5 to 2.1 0.886 
18 -1.1 -4.1 to 1.9 0.447 
24 -1.0 -4.0 to 1.9 0.459 
Table 83 Comparison between COCP and no treatment Brief Profile of Female Sexual Function 






4.18 Short Form-36 
Results are shown as mean (standard deviation) when normally distributed and median (25, 
75%) when not normally distributed.  Comparisons between groups were carried out using 
linear regression with adjustment for baseline score in the case of normally distributed data, or 
the Mann-Whitney U test where data are not normally distributed.  In several of the domains, 
there are no changes from baseline over the duration of the trial (especially in the HRT and no 
treatment groups) and graphs are not shown in these cases.  In both the HRT and the COCP 
groups, there were a few women whose scores rose dramatically in most domains from 3 
months, indicating that treatment can have huge positive effects on quality of life in some 
women.  However, due to the distribution of the data and the fact that this did not occur in most 





4.18.1 Physical functioning 
Table 84 Short Form-36 (SF-36) physical functioning results 
 
Mann-Whitney U tests revealed a significant difference between the changes in score in the 
HRT and COCP groups at 6 months but not at any other time-points (p values 0.513, 0.048, 
0.306, 0.526 and 0.429 at 3, 6, 12, 18 and 24 months).  This raises the suspicion that the p 
value of <0.05 at 6 months was due to chance. There were no significant differences between 
the changes in the HRT and no treatment groups (p values 0.054, 0.267, 0.190, 0.784 and 
0.261 at 3, 6, 12, 18 and 24 months).  Comparison between the COCP and no treatment groups 
revealed significant differences at 6 and 12 months (p values 0.583, 0.005, 0.035, 0.388 and 
0.097 at 3, 6, 12, 18 and 24 months).   
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Table 85 Short Form-36 (SF-36) role-physical results 
 
Mann-Whitney U tests did not show any significant differences between the changes in score in 
the HRT and COCP groups at any time-point (p values 0.240, 0.143, 0.904, 0.941 and 0.128 at 
3, 6, 12, 18 and 24 months).  There were significant differences between the changes in the 
HRT and no treatment groups at 3 and 12 months but not at the other time-points (p values 
0.026, 0.171, 0.017, 0.088 and 0.115 at 3, 6, 12, 18 and 24 months).  Comparison between the 
COCP and no treatment groups revealed significant differences at 3, 6 and 24 months (p values 
0.008, 0.011, 0.208, 0.263 and 0.003 at 3, 6, 12, 18 and 24 months).  
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4.18.3 Bodily Pain 
Table 86 Short Form-36 (SF-36) bodily pain results 
Mann-Whitney U tests did not show any significant differences between the changes in score in 
any of the groups at any time-point (p values for HRT versus COCP group 0.678, 0.387, 0.552, 
0.826 and 0.913 at 3, 6, 12, 18 and 24 months; p values for HRT vs no treatment group 0.834, 
0.398, 0.169, 0.323 and 0.772 at 3, 6, 12, 18 and 24 months; p values for COCP vs no 
treatment group 0.473, 0.082, 0.566, 0.233 and 0.665 at 3, 6, 12, 18 and 24 months).   
  
























































































4.18.4 General Health 
Linear regression with adjustment for baseline score did not show any differences between the 
groups (tables 88 to 90). 
 
Table 87 Short Form-36 (SF-36) general health results 
 




































































Figure 45 Changes from baseline in Short Form-36 (SF-36) General Health mean score over 24 





Figure 46 Changes in mean Short Form-36 (SF-36) general health score over 24 months in 
participants with complete data collection 
4.18.4.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean SF-36 general 
health score 
95% confidence 
interval of the 
difference 
p value 
3 0.19 -7.8 to 8.2 0.962 
6 0.94 -8.7 to 10.5 0.841 
12 -2.8 -13.2 to 7.7 0.588 
18 -2.0 -10.5 to 6.4 0.621 
24 -4.5 -14.6 to 5.6 0.359 
Table 88 Comparison between HRT and COCP Short Form-36 (SF-36) general health score 




4.18.4.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean SF-
36 general health 
score 
95% confidence 
interval of the 
difference 
p value 
3 3.3 -5.9 to 12.6 0.469 
6 0.7 -5.7 to 7.1 0.822 
12 5.0 -5.2 to 15.2 0.325 
18 3.0 -7.5 to 13.5 0.559 
24 -0.8 -10.4 to 8.8 0.862 
Table 89 Comparison between HRT and no treatment Short Form-36 (SF-36) general health 
score results.  Linear regression analysis was used to adjust for baseline score 
 
4.18.4.3 Comparison between COCPand no treatment groups 
Months COCP minus no 
treatment mean SF-
36 general health 
score 
95% confidence 
interval of the 
difference 
p value 
3 2.1 -3.0 to 7.3 0.402 
6 1.3 -2.7 to 5.3 0.513 
12 1.5 -4.7 to 7.7 0.625 
18 2.5 -3.3 to 8.4 0.383 
24 -1.7 -8.1 to 4.8 0.594 
Table 90 Comparison between COCP and no treatment Short Form-36 (SF-36) general health 








Figs 47 and 48 show that the vitality score remained relatively constant in the no treatment 
group but increased in both the HRT and COCP groups.  This effect appears more marked in 
the HRT group but this only reached a significance level of <0.05 at 3 and 18 months.  Amongst 
women who completed the trial, those in the COCP group had a lower baseline vitality score 
than those in the HRT group.  
 
Table 91 Short Form-36 (SF-36) vitality results 




































































Figure 47 Changes from baseline in Short Form-36 (SF-36) vitality score over 24 months 





Figure 48 Changes in mean Short Form-36 (SF-36) vitality score over 24 months in participants 
with complete data collection 
4.18.5.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean SF-36 vitality 
score 
95% confidence 
interval of the 
difference 
p value 
3 -14.1 -24.4 to -3.8 0.009 
6 -6.4 -16.6 to 3.8 0.207 
12 -11.3 -23.6 to 1.0 0.070 
18 -15.4 -28.7 to -2.1 0.025 
24 -10.4 -26.9 to 6.2 0.205 
Table 92 Comparison between HRT and COCP Short Form-36 (SF-36) vitality score results.  




4.18.5.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean SF-
36 vitality score 
95% confidence 
interval of the 
difference 
p value 
3 11.0 1.8 to 20.1 0.021 
6 8.9 -1.5 to 19.2 0.091 
12 22.1 8.3 to 35.9 0.003 
18 15.3 2.2 to 28.4 0.024 
24 12.5 -1.1 to 26.0 0.070 
Table 93 Comparison between HRT and no treatment Short Form-36 (SF-36) vitality score 
results.  Linear regression analysis was used to adjust for baseline score 
 
4.18.5.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean SF-
36 vitality score 
95% confidence 
interval of the 
difference 
p value 
3 -1.9 -5.9 to 2.1 0.343 
6 1.2 -3.5 to 6.0 0.595 
12 5.2 -2.6 to 13.0 0.185 
18 2.6 -5.0 to 10.1 0.490 
24 1.4 -6.4 to 9.2 0.712 
Table 94 Comparison between COCP and no treatment Short Form-36 (SF-36) vitality score 








4.18.6 Social Functioning 
Table 95 Short Form-36 (SF-36) social functioning results 
Mann-Whitney U tests showed few significant differences between the groups (p values for HRT 
versus COCP group 0.495, 0.116, 0.731, 0.702 and 0.786 at 3, 6, 12, 18 and 24 months; p 
values for HRT vs no treatment group 0.138, 0.063, 0.039, 0.024 and 0.147 at 3, 6, 12, 18 and 
24 months; p values for COCP vs no treatment group 0.642, 0.003, 0.204, 0.200 and 0.389 at 3, 
6, 12, 18 and 24 months).  The significant differences that were found were inconsistent and 
may to be due to chance.   
  

























































































4.18.7 Role Emotional 
Table 96 Short Form-36 (SF-36) role-emotional results 
Mann-Whitney U tests comparing the HRT and COCP groups showed a significant difference at 
24 months but not other time-points (p values 0.882, 0.108, 0.546, 0.197 and 0.035 at 3, 6, 12, 
18 and 24 months.  The comparison between the HRT and no treatment groups showed 
significant differences at 3 and 12 months only (p values 0.032, 0.217, 0.021, 0.175 and 0.249 
at 3, 6, 12, 18 and 24 months).  The COCP and no treatment groups were found to be 
significantly different at all time-points except 3 months (p values 0.149, 0.015, 0.012, 0.041 and 
0.014 at 3, 6, 12, 18 and 24 months).   
  




















































































4.18.8 Mental Health 
The mental health score improved in both the HRT and COCP groups, with larger changes 
seen in the HRT group.  The differences between the HRT and COCP groups were not 
statistically significant.  The HRT group had a statistically significantly increased score 
compared with the no treatment group at all time-points.  There were no significant differences 
between the COCP and no treatment groups.  These trends concord with the trends observed 
in the Patient Health Questionnaire-9 results. 
 
Table 97 Short Form-36 (SF-36) mental health results 




































































Figure 49 Changes from baseline in Short Form-36 (SF-36) mental health score over 24 months 





Figure 50 Changes in mean Short Form-36 (SF-36) mental health score over 24 months in 
participants with complete data collection 
4.18.8.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean SF-36 mental 
health score 
95% confidence 
interval of the 
difference 
p value 
3 -8.7 -17.5 to 0.1 0.053 
6 -8.1 -18.1 to 1.8 0.103 
12 -8.5 -21.4 to 4.5 0.188 
18 -9.0 -24.0 to 6.0 0.225 
24 -3.9 -17.3 to 9.5 0.550 
Table 98 Comparison between HRT and COCP Short Form-36 (SF-36) mental health score 




4.18.8.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean SF-
36 mental health 
score 
95% confidence 
interval of the 
difference 
p value 
3 10.8 2.9 to 18.7 0.009 
6 13.6 3.6 to 23.5 0.009 
12 16.0 4.9 to 27.1 0.006 
18 17.0 6.0 to 28.0 0.004 
24 10.3 1.6 to 19.0 0.022 
Table 99 Comparison between HRT and no treatment Short Form-36 (SF-36) mental health 
score results.  Linear regression analysis was used to adjust for baseline score 
 
4.18.8.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean SF-
36 mental health 
score 
95% confidence 
interval of the 
difference 
p value 
3 0.7 -3.7 to 5.2 0.737 
6 2.8 -3.3 to 8.8 0.353 
12 4.5 -3.1 to 12.0 0.236 
18 5.9 -1.9 to 13.7 0.133 
24 4.1 -2.6 to 10.8 0.214 
Table 100 Comparison between COCP and no treatment Short Form-36 (SF-36) mental health 





4.18.9 Physical Component Score 
Fig 51 suggests higher increases in score in the COCP group compared with the other groups.  
However, this is not seen among the women with complete data collection (fig 52) and on 
formal comparison there are no differences between any of the groups. 
 
Table 101 Short Form-36 (SF-36) physical component score results 





































































Figure 51 Changes from baseline in Short Form-36 (SF-36) physical component score over 24 





Figure 52 Changes in mean Short Form-36 (SF-36) physical component score over 24 months 
in participants with complete data collection 
4.18.9.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 




interval of the 
difference 
p value 
3 0.5 -2.6 to 3.6 0.756 
6 1.5 -1.7 to 4.7 0.336 
12 0.2 -4.0 to 4.4 0.929 
18 -2.2 -6.2 to 1.9 0.273 
24 -2.9 -7.2 to 1.4 0.169 
Table 102 Comparison between HRT and COCP Short Form-36 (SF-36) summary physical 




4.18.9.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 0.1 -3.2 to 3.4 0.948 
6 1.7 -2.6 to 6.0 0.433 
12 0.0 -3.4 to 3.5 0.978 
18 1.0 -4.1 to 6.1 0.687 
24 1.0 -3.2 to 5.2 0.625 
Table 103 Comparison between HRT and no treatment Short Form-36 (SF-36) physical 
component score results.  Linear regression analysis was used to adjust for baseline score 
 
4.18.9.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean SF-
36 physical 
component score  
95% confidence 
interval of the 
difference 
p value 
3 0.8 -1.0 to 2.6 0.350 
6 1.6 -0.7 to 3.9 0.167 
12 0.4 -1.8 to 2.5 0.729 
18 -0.1 -3.1 to 2.9 0.937 
24 0.5 -2.3 to 3.3 0.708 
Table 104 Comparison between COCP and no treatment Short Form-36 (SF-36) physical 





4.18.10 Mental Component Score 
The mental component score increased in both the HRT and COCP groups, although it took 
longer (6 months) in the COCP group, as seen in some of the other questionnaires.  There are 
no significant differences between the HRT and COCP groups.  The changes in the HRT and 
no treatment groups are statistically significantly different at all time points except 24 months, 
when the p value is 0.070.  Comparison between the COCP and no treatment groups did not 
show any differences.  
Table 105 Short Form-36 (SF-36) mental component score results 





































































Figure 53 Changes from baseline in Short Form-36 (SF-36) mental component score over 24 






Figure 54 Changes in mean Short Form-36 (SF-36) mental component score over 24 months in 
participants with complete data collection 
4.18.10.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean SF-36 mental 
component score 
95% confidence 
interval of the 
difference 
p value 
3 -5.4 011.4 to 0.5 0.071 
6 -1.2 -6.4 to 3.9 0.627 
12 -4.0 -12.5 to 4.4 0.333 
18 -6.5 -16.6 to 3.6 0.192 
24 -1.0 -9.1 to 7.0 0.789 
Table 106 Comparison between HRT and COCP Short Form-36 (SF-36) mental component 




4.18.10.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean SF-
36 mental component 
score 
95% confidence 
interval of the 
difference 
p value 
3 5.7 0.9 to 10.5 0.021 
6 6.2 0.7 to 11.8 0.029 
12 11.5 4.6 to 18.5 0.002 
18 10.1 4.2 to 16.1 0.003 
24 5.5 -0.5 to 11.5 0.070 
Table 107 Comparison between HRT and no treatment Short Form-36 (SF-36) mental 
component score results.  Linear regression analysis was used to adjust for baseline score 
 
4.18.10.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean SF-
36 mental component 
score 
95% confidence 




3 -0.1 -3.1 to 2.9 0.950 
6 2.3 -1.1 to 5.6 0.176 
12 4.1 -0.6 to 8.8 0.086 
18 3.5 -1.6 to 8.6 0.168 
24 2.2 -2.1 to 6.6 0.291 
Table 108 Comparison between COCP and no treatment Short Form-36 (SF-36) mental 





4.18.11 Health Transition 
Fig 55 shows that the health transition score in both the HRT and COCP groups improved over 
the course of the trial.  By 6 months none of the participants in the treatment groups rated their 
health as worse than a year ago, although at 24 months one participant in the COCP group 
gave a score of somewhat worse than a year ago.  More women in the HRT group than the 
COCP group rated their health as ‘much better’.  Improvements were also seen in the no 
treatment group, but this was largely due to women with lower scores withdrawing from the trial. 
 
Table 109 HRT group responses to the question ‘Compared to one year ago, how would you 
rate your health in general now?’  
 
 Baseline 3 months 6 months 12 months 18 months 24 months 
Much better (%) 7 8 0 0 0 0 
Somewhat better (%) 13 31 17 27 20 22 
About the same (%) 47 46 75 64 60 44 
Somewhat worse (%) 33 15 8 9 20 22 
Much worse (%) 0 0 0 0 0 11 
Table 110 COCP group responses to the question ‘Compared to one year ago, how would you 
rate your health in general now?’  
  
 Baseline 3 months 6 months 12 months 18 months 24 months 
Much better (%) 0 21 23 23 18 33 
Somewhat better (%) 27 29 31 23 36 25 
About the same (%) 33 43 46 46 46 42 
Somewhat worse (%) 20 0 0 8 0 0 




 Baseline 3 months 6 months 12 months 18 months 24 months 
Much better (%) 17 12 9 10 13 0 
Somewhat better (%) 17 16 17 20 20 20 
About the same (%) 55 56 61 65 60 73 
Somewhat worse (%) 7 12 13 5 7 7 
Much worse (%) 3 4 0 0 0 0 
Table 111 No treatment group responses to the question ‘Compared to one year ago, how 
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HRT
much better somewhat better about the same
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much better somewhat better about the same
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No treatment
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4.19 Patient Health Questionnaire-9 
The Patient Health Questionnaire-9 (PHQ-9) data were not normally distributed.  Therefore data 
are shown as median (25%, 75%).  Manipulation of the data was unable to produce a normal 
distribution and therefore the non-parametric Mann-Whitney U test was used to compare 
changes between groups.  This does not provide estimation of difference in size effect between 
the groups and does not allow for adjustment for baseline score.  This is particularly relevant 
because as shown in fig 57 the women who completed the trial in the COCP group had a higher 
baseline score than those in the HRT and no treatment groups.  Fig 56 shows that there was a 
reduction in PHQ-9 score from baseline at all time-points in the HRT group and at all time-points 
except 3 months in the COCP group, but no changes were seen in the no treatment group.   
Table 112 Patient Health Questionnaire-9 (PHQ-9) results 











































































Figure 56 Changes from baseline in Patient Health Questionnaire-9 (PHQ-9) median score over 






Figure 57 Changes in median Patient Health Questionnaire-9 (PHQ-9) score over 24 months in 
participants with complete data collection 
 
Mann-Whitney U tests revealed no significant differences between the changes in score in the 
HRT and COCP groups at 3, 6, 12, 18 or 24 months (p values 0.064, 0.682, 0.309, 0.595 and 
0.886 respectively).  There were also no significant differences between the changes in the 
COCP and no treatment groups (p values 0.988, 0.090, 0.113, 0.191 and 0.134 at 3, 6, 12, 18 
and 24 months).  However, comparison between the HRT and no treatment groups revealed 
significant differences at all time points except 24 months (p values 0.024, 0.028, 0.001, 0.006 







4.20 Blood pressure  
Looking at all available data (fig 58 and 60), it appears that the COCP causes a slight rise in 
diastolic and systolic blood pressure as compared with HRT or no treatment.  However, this is 
not seen on observing data solely from participants with complete data collection (figs 59 and 
61).  Significant differences were found on comparison between HRT and COCP at 3 months in 
both diastolic and systolic blood pressure.  On comparison with the no treatment group, the only 
significant difference found was at 3 months between the COCP and no treatment groups.  A 
lack of detection of further differences is likely to be due to the small numbers in this trial. 
4.20.1 Systolic blood pressure 
Table 113 Systolic blood pressure (SBP) results (mmHg) 





































































Figure 58 Changes from baseline in mean systolic blood pressure (mmHg) over 24 months 





Figure 59 Changes in mean systolic blood pressure (mmHg) over 24 months in participants with 
complete data collection 
4.20.1.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean systolic blood 
pressure  
95% confidence 
interval of the 
difference 
p value 
3 10.2 0.6 to 19.8 0.038 
6 5.2 -5.4 to 15.8 0.317 
12 5.2 -3.6 to 14.1 0.231 
18 4.1 -8.1 to 16.3 0.492 
24 0.3 -12.2 to 12.9 0.959 
Table 114 Comparison between HRT and COCP systolic blood pressure (mmHg) results.  




4.20.1.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 -2.0 -9.2 to 5.1 0.573 
6 -3.0 -11.3 to 5.4 0.475 
12 3.1 -4.6 to 10.7 0.423 
18 0.3 -9.1 to 9.7 0.949 
24 2.8 -7.0 to 12.6 0.562 
Table 115 Comparison between HRT and no treatment systolic blood pressure (mmHg) results.  
Linear regression analysis was used to adjust for baseline score. 
 
4.20.1.3 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 3.1 -0.7 to 6.9 0.108 
6 0.6 -3.2 to 4.5 0.745 
12 3.4 -0.2 to 6.9 0.062 
18 1.8 -1.5 to 5.2 0.272 
24 1.4 -2.5 to 5.3 0.465 
Table 116 Comparison between COCP and no treatment systolic blood pressure (mmHg) 





4.20.2 Diastolic blood pressure 
Table 117 Diastolic blood pressure (DBP) results (mmHg) 
  





































































Figure 60 Changes from baseline in mean diastolic blood pressure (mmHg) over 24 months 






Figure 61 Changes in mean diastolic blood pressure (mmHg) over 24 months in participants 
with complete data collection 
4.20.2.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean diastolic blood 
pressure  
95% confidence 
interval of the 
difference 
p value 
3 6.0 2.0 to 9.9 0.005 
6 1.5 -6.1 to 9.0 0.694 
12 0.5 -7.2 to 8.3 0.888 
18 2.7 -5.2 to 10.6 0.483 
24 4.2 -3.7 to 12.0 0.281 
Table 118 Comparison between HRT and COCP diastolic blood pressure (mmHg) results.  




4.20.2.2 Comparison between HRT and no treatment groups 





interval of the 
difference 
p value 
3 0.3 -4.3 to 4.8 0.913 
6 -0.4 -6.3 to 5.5 0.884 
12 3.8 -1.6 to 9.2 0.159 
18 2.6 -4.6 to 9.8 0.458 
24 3.1 -3.9 to 10.0 0.372 
Table 119 Comparison between HRT and no treatment diastolic blood pressure (mmHg) results.  
Linear regression analysis was used to adjust for baseline score. 
 
4.20.2.3 Comparison between COCP and no treatment groups 





interval of the 
difference 
p value 
3 2.9 0.2 to 5.5 0.035 
6 0.4 -3.1 to 4.0 0.814 
12 1.9 -1.7 to 5.5 0.287 
18 2.6 -1.5 to 6.7 0.202 
24 2.8 -1.4 to 7.1 0.181 
Table 120 Comparison between COCP and no treatment diastolic blood pressure (mmHg) 






4.21 Body mass index 
Both the graph showing changes from baseline using all available data at each time-point (fig 
62) and the graph displaying results from participants with complete data collection (fig 63) 
show that in the COCP and no treatment groups the body mass index (BMI) had an upwards 
trend.  This was more marked in the COCP group.  In the HRT group the BMI remained 
relatively constant.  However, when compared formally there were no statistically significant 
differences between any of the groups. 
 
Table 121 Body mass index (BMI) results (kg/m2) 
 
















Baseline BMI 15 25.1  
(3.6) 
15 23.9  
(4.6) 
29 24.2  
(3.2) 
Change from 














































Figure 62 Changes from baseline in body mass index (BMI) (kg/m2) mean score over 24 months 















Figure 63 Changes in mean body mass index (BMI) (kg/m2) score over 24 months in 
participants with complete data collection 
4.21.1 Comparison between HRT and COCP groups 
Months COCP minus HRT 
mean BMI (kg/m2) 
95% confidence 
interval of the 
difference 
p value 
3 -0.0 -0.6 to 0.5 0.899 
6 -0.0 -0.8 to 0.7 0.929 
12 0.3 -0.6 to 1.2 0.555 
18 0.6 -0.3 to 1.4 0.180 
24 0.7 -0.4 to 1.8 0.216 
Table 122 Comparison between HRT and COCP body mass index (BMI) (kg/m2) results.  Linear 




4.21.2 Comparison between HRT and no treatment groups 
Months HRT minus no 
treatment mean BMI 
(kg/m2) 
95% confidence 
interval of the 
difference 
p value 
3 -0.3 -0.8 to 0.2 0.270 
6 0.1 -0.7 to 0.8 0.841 
12 0.2 -0.6 to 0.9 0.653 
18 -0.6 -1.7 to 0.5 0.254 
24 -0.2 -1.2 to 0.9 0.765 
Table 123 Comparison between HRT and no treatment body mass index (BMI) (kg/m2) results.  
Linear regression analysis was used to adjust for baseline score. 
 
4.21.3 Comparison between COCP and no treatment groups 
Months COCP minus no 
treatment mean BMI 
(kg/m2) 
95% confidence 
interval of the 
difference 
p value 
3 -0.1 -0.4 to 0.1 0.363 
6 0.0 -0.4 to 0.4 0.886 
12 0.2 -0.2 to 0.6 0.257 
18 -0.0 -0.6 to 0.5 0.895 
24 0.3 -0.3 to 0.8 0.368 
Table 124 Comparison between COCP and no treatment body mass index (BMI) (kg/m2) 





Chapter 5 Discussion 
The main initial obstacle to progression of the trial was recruitment, which was much slower 
than anticipated.  Recruitment to the treatment group was particularly difficult as there were few 
recently diagnosed women who wanted to take treatment but did not mind if they took HRT or 
the COCP.  Many did not want to jeopardise the small but real possibility of spontaneous 
pregnancy with the chance of being randomised to COCP, but would have participated if the 
study had been comparing two different HRT preparations.  There were also women who were 
already settled on treatment and did not want to complete a two month washout period prior to 
randomisation.  We anticipated that there would be fewer women wanting to join the no 
treatment group, but in fact women who had already decided they did not wish to take treatment 
welcomed the opportunity to be closely monitored and recruitment to this group was completed 
first.  Women choosing no treatment were fully counselled on the benefits of oestrogen 
replacement both before taking part and throughout the trial.  Despite spending more time 
discussing this than would normally be available in clinic, only a few changed their minds and 
opted for treatment.  There will always be women who decline treatment for various reasons 
and this trial provides valuable data on what these women can expect, especially regarding 
bone density and symptoms.  It is important to remember that these women continued to 
choose to decline treatment at each time-point and that there were several who withdrew 
because of symptoms or a drop in bone density causing them to opt for treatment.  Recruitment 
was closed after two years due to time constraints and at this point there were 15 women 
(rather than the planned 22) in each treatment group.  The three year from diagnosis cut-off for 
recruitment into the study was chosen because bone density changes the most in the early 
years following diagnosis.  However in retrospect, particularly for the treatment groups, it may 
have been reasonable to expand this to five years from diagnosis.  The use of varied 
preparations of COCP and HRT may also have improved recruitment and also retention in the 
study as some women did not want to take a particular brand or wanted the option to change if 
it did not suit them, as is common in clinical practice.  However this would then have made 
interpretation of the results more difficult, particularly with the small numbers in the trial. 
The main limitations of this trial were the small sample size and the high drop-out rate, which 
unfortunately occurred to a greater extent in the COCP than the HRT group.  One participant in 
each of these groups withdrew due to symptoms of depression and one in each group because 
of side effects.  The excess drop-out rate in the COCP group was due to loss of follow up.  
Every effort was made to determine other possible reasons for withdrawal but none could be 
obtained.  There is therefore a higher level of missing data in the COCP group.  One method to 
accommodate for missing data would have been multiple imputation, which is the process of 
filling in missing data using probable values gained from all other information (164).  In the 
absence of expert dedicated statistical assistance this was not feasible in this trial but it would 
need to be a consideration in planning further trials in this area.  In some fields women with 
complete data collection in the COCP group appear to have different baseline values compared 
with women with complete data collection in the HRT group.  This is particularly striking in the 




protein but not seen in the lumbar spine bone density or lipid results.  As the groups were 
randomised at baseline, it can be assumed that values were comparable at this point and this is 
confirmed by the baseline data tables.  Differences in baseline values in women with complete 
data collection are therefore due to differences in those who withdrew.  This point has been 
illustrated by displaying graphs throughout the results showing not only changes from baseline 
using all available data at each time-point but also showing the absolute values for each 
variable amongst participants with complete data collection.  The possibility that women in the 
HRT group with poor baseline symptom scores were lost to follow up because of a lack of 
improvement of their symptoms cannot be excluded.  However, this would not explain why 
women in a similar position in the COCP group did not withdraw.  It seems likely that baseline 
differences in women who withdrew from each group are due to chance.  These baseline 
differences are compensated to some extent by using adjustment for baseline score in 
statistical analysis where possible (for variables with normal distributions).  Although the drop-
out rate is high, it is worth noting that in the only other similar trial to this, there was a drop-out 
rate of 47% (83), compared with 30% in the treatment arms of this trial.  Women received 
continuity of care and flexibility with appointments and it is difficult to see how loss of follow up 
where no reason was given could have been improved.  This will need to be considered in 
planning future trials in this groups of women.  The compliance with medication calculated from 
returned pills was very high (over 95%).  Whilst we did not perform independent markers of 
compliance with medication such as FSH levels, unscheduled bleeding was considered to be an 
adverse event and was not reported in either treatment group, suggesting good compliance.   
Another limitation is that the no treatment group was not randomised.  The main comparisons of 
value are those between the HRT and COCP groups.  However, comparisons between each of 
these groups and the no treatment group have been included because they illustrate differences 
between women who choose (and continue to choose) to take no treatment and those who 
choose to take treatment and are randomised to a particular group.  In some parameters, there 
can be no doubt that treatment is highly beneficial.  For example in the bone density results, the 
bone density at the hip is maintained in both the HRT and COCP groups and falls at every time-
point in the no treatment group.  Statistical comparison reveals highly significant differences at 
all time-points between the no treatment group and each of the treatment groups.  At the spine, 
HRT is again clearly better than no treatment, but although COCP shows a trend towards 
benefit, the results are not statistically significantly different.  A larger sample size would be 
needed to detect a difference. 
Of the few trials in the area of POF, most use a cut-off age of under 40 rather than under 45.  
An age of 44 or less was used in this trial because the primary outcome was bone density and 
this, along with many of the other outcomes in this study, continues to be a concern for women 
with ovarian failure in their early 40s.  Using an age limit of 44 made recruitment possible; if we 
had used an upper limit of 39 only 27 women would have been recruited.  The median age in 
this study was 40.5.  This age group of women have busy lives and frequently needed to re-
arrange their appointments because of work or family life.  Those who withdrew were not 




Baseline data in this trial reveal some interesting results.  For example, looking at data from all 
groups, 60% of women at baseline report reduced libido, 58% a lack of energy and 58% 
irritability.  These are symptoms which may not be covered in a routine consultation, especially 
in the time constraints of general practice, but have the potential to have a large impact on 
quality of life.  Menopausal symptom depression scores were higher and mental health scores 
lower in the women who opted for treatment rather than no treatment.  Of note, there were no 
significant differences in bone density in women choosing no treatment or treatment and the 
mean baseline Z scores were -0.6, -0.5 and -0.6 in the HRT, COCP and no treatment groups 
respectively.  This is higher than found in most cross-sectional studies investigating BMD in 
POF and is presumably due to the relatively short time since diagnosis.   
In the bone density results, the most significant findings were at the lumbar spine, which is 
recognised to be the best site for monitoring response to treatment (64).  HRT increased bone 
density at the lumbar spine whereas COCP only maintained it and this was significant at 12 and 
24 months.  Importantly, in participants with complete data collection the baseline lumbar spine 
BMD was similar in the HRT and COCP groups and so the differences cannot be explained by 
the HRT group having a significantly lower initial bone density.  However, the bone marker 
results did not show any significant differences between the HRT and COCP groups.  The lack 
of a significant difference between the treatment groups in the bone markers is likely to be due 
to the high variability of these markers.  The only other prospective trial comparing HRT and 
COCP in POF (Crofton et al) investigated bone density and bone turnover markers in a 
crossover trial with 12 months each of HRT and COCP; differences were found in markers of 
bone formation (ALP and P1NP) in favour of HRT but no significant differences were found in 
bone density or CTX (83).  This discrepancy with our results could be explained by the relatively 
higher doses of oestrogen in the HRT used in Crofton et al’s study (transdermal oestradiol 
100mcg for 1 week then 150mg for weeks 2-4).  A lack of difference between COCP and HRT 
in the bone markers in our trial means that the differences in bone density between these 
groups need to be interpreted with caution, especially in light of the high drop-out rate in the 
COCP group.  However, in the absence of any other data from clinical trials, it seems 
reasonable to inform women that HRT appears to have a better effect on bone density than the 
COCP.  A recent Cochrane review on contraceptives and bone density did not find any effect of 
combined oral contraceptives on bone density in healthy adults but acknowledged that bone 
density may be affected by COCP use in adolescent and young women (165).  It is important to 
remember that some women with POF will be starting oestrogen replacement before they have 
reached their peak bone mass and taking it for many years and whilst the COCP may be a 
more natural choice for this age group, it is probably not the best oestrogen replacement for 
their bone development.  Further research in this group of women in particular is required.   
There are several possible reasons for the significant difference between HRT and COCP in 
lumbar spine bone density.  The COCP was used in its traditional way, with 3 weeks of pills 
followed by a hormone free week.  It is possible that this oestrogen-free week affected bone 
mass acquisition.  The types of oestrogen are also different and oestradiol may have a more 




but at different doses (75mcg in Nuvelle and 150mcg in the COCP), and with Nuvelle 
progesterone is only taken for 12 days a month rather than 21.  Although oestrogens are usually 
considered to be the main factor in HRT affecting bone density, levonorgestrel is an androgenic 
progesterone and may affect the bone in high concentrations (166).  There is a theory is that in 
lower doses levonorgestrel has a direct stimulatory effect on osteoblasts via progesterone and 
androgen receptors and can help to increase bone mass, but at higher doses some can also 
bind to glucocorticoid receptors and inhibit osteoblasts in a dose-dependent manner.   
In the no treatment group, there was a reduction in bone density at all sites by 24 months and 
significant differences in bone markers when compared with both HRT and COCP at each time 
point.  From these results it is reasonable to conclude that women who choose not to take any 
form of hormone replacement will suffer adverse effects on their bone health compared with 
those who opt for either HRT or the COCP.  Women should be urged to take some form of 
oestrogen replacement rather than none.   
It was very disappointing that all but one of the AMH levels was undetectable.  Previous cross-
sectional studies investigating AMH in POF have shown detectable levels in up to 23% (24, 
133).  Even accounting for an older age group in this trial, it is surprising that there are not more 
detectable levels.  Although the product literature advises that samples are stable when frozen, 
concerns have recently been raised about the stability of storage of samples which are 
analysed using the AMH Gen II assay (167, 168).  Samples analysed in this study used the 
recommended pre-mix protocol to eliminate complement interference which can cause falsely 
low AMH levels, which should have eliminated this problem.   
Inhibin B has been reported as an inferior marker of ovarian failure (120), although it has been 
noted to relate to the presence of ovarian follicles in POF (134).  It is interesting that out of the 
17 participants who had at least one detectable level, 11 had a detectable level on another 
occasion.  Inhibin B may warrant further investigation in POF in the detection of intermittent 
ovarian function.  Only one participant had a detectable inhibin B level at every visit.  There 
were more detectable levels at baseline than at 24 months (even allowing for drop-outs), which 
suggests there is more ovarian activity close to the time of diagnosis, as has been previously 
described (3). 
Although there were no statistically significant differences between any of the groups on lipid 
profile, the trend of reduction of LDL with HRT was seen in another study in POF patients (98).  
This study also reported an increase in TG with HRT which was not seen in our study.  The 
trends we found in LDL and HDL were in favour of HRT compared with COCP.  This is as 
expected with the oestrogens and progestogen in the preparations used (169, 170).  High-
sensitivity CRP was increased in the COCP group, but this is difficult to interpret because this 
group had a lower level at baseline and the non-parametric distribution of the data (which could 
not be transformed to a normal distribution) meant that regression analysis with adjustment for 




The Modified Greene Climacteric Scale (MGCS) results showed rapid reductions in symptom 
scores following initiation of HRT, as seen at the time of the normal menopause (53).  
Reductions in symptom score were also seen with the COCP, but maximal effects were seen at 
6 months rather than 3 months with HRT; the exception to this was vasomotor symptoms which 
were controlled equally quickly.  This delayed effect in the COCP group was also observed in 
the Menopause Symptoms Treatment Satisfaction Questionnaire results and the Mental 
Component Score of the Short Form-36.  MGCS scores at 24 months indicate better symptom 
control with HRT compared with COCP in all domains except vasomotor and sexual function, 
which as a single question is unlikely to be sensitive enough to ascertain a difference.  Baseline 
MGCS scores were similar to those observed in general menopause clinics.  The Menopause 
Symptoms Treatment Satisfaction Questionnaire results are difficult to interpret in view of the 
discrepancy between baseline scores in those who withdrew from each of the treatment groups.  
As there is no baseline score adjustment for this cannot be performed.  Despite this, there 
appears to be a higher satisfaction with treatment at each time point in the HRT group, and this 
is highly significant at 3 months (p 0.003) when there was a good amount of data collection, 
confirming the findings in the MGCS of a delay in symptom control with the COCP. 
The results from the Brief Profile of Female Sexual Function questionnaire are very interesting, 
especially in view of sexual function being identified as a matter of high concern to women with 
POF (55).  The baseline scores of 18 in both the treatment groups and 20 in the no treatment 
group show high levels of sexual dysfunction (a score of 20 or less indicates hypoactive sexual 
desire disorder). From a similar baseline score in the HRT and COCP groups, even amongst 
women who completed the trial, the HRT group’s score increased whereas that of the COCP 
group remained stable.  However these differences did not reach statistical significance.  Sexual 
function in the COCP and no treatment groups remained similar to baseline levels throughout 
the trial.  In the general population it is recognised the COCP increases sex hormone binding 
globulin which in turn reduces the free testosterone level (171) and this has been found to be 
associated with the presence of hypoactive sexual desire disorder (172).  A 2009 internet-based 
survey on sexual dysfunction including 2527 peri- and post-menopausal women reported that 
over one third of those who had tried HRT found that it improved symptoms of sexual 
dysfunction (173).  Although the results in our study did not reach statistical significance, in view 
of other evidence, it seems reasonable to suggest a potential benefit of HRT over the COCP for 
women with POF who have a particular issue with sexual dysfunction.   
The Short Form-36 quality of life questionnaire did not show any consistent differences between 
the groups in most domains.  In the vitality domain, there was a non-significant improvement in 
score in both of the treatment groups.  The statistical comparison between the HRT and no 
treatment groups in this domain was significant at all but one time-point, but no differences were 
demonstrated between the COCP and no treatment groups.  In the Role Emotional domain, the 
COCP was significantly better than HRT at 24 months, although not at other time-points, and 
the COCP was better than no treatment at every time-point except 3 months.  The mental 
health score improved in both the HRT and COCP groups, with no significant differences 




significant.  In response to the health transition question, at 24 months in the HRT group 33% 
rated their health as much better than a year ago; 25% said it was somewhat better; 42% 
reported it was about the same; 0% somewhat worse and 0% much worse.  By comparison, in 
the COCP group the figures were 0% (much better); 22% (somewhat better); 44% (about the 
same); 22% somewhat worse and 11% much worse.  The baseline scores in the COCP group 
were lower than those in the HRT group and the scores in both treatment groups improved over 
the course of the trial.   
The Patient Health Questionnaire-9 assessment of depression shows reduction in scores in the 
HRT and COCP groups but not in the no treatment group.  Significant differences were found 
between the HRT and no treatment groups at every time-point except 24 months.  Unfortunately 
as the data were not normally distributed there could be no adjustment for baseline score, which 
was higher in the COCP group in women who completed the trial.   
The COCP group had a slight rise in both systolic and diastolic blood pressure, evident from 3 
months, although it was only significantly different from the HRT group at 3 months.  This was 
not seen in the HRT or no treatment groups, whose values remained relatively stable 
throughout the trial.  A similar increase in blood pressure with COCP was seen in a crossover 
trial of women with POF taking COCP and HRT for a year each (101); 18 women completed 
both regimens and a mean difference of systolic blood pressure of 7.3mmHg and diastolic blood 
pressure of 7.4mmHg were found following 12 months treatment.  These are similar to the 
numbers obtained in our study at 3 months and it is likely that significant differences were not 
found later on due to reduced numbers of women continuing in the trial.  Body mass index had 
an upward trend in the COCP and no treatment groups and remained stable in the HRT group, 
but none of the groups had significantly different changes on statistical analysis.  A larger 








Chapter 6 Conclusion 
Although this trial has limitations of small sample size and high drop-out rate in the COCP 
group, it makes a significant contribution to the very small body of evidence concerning the 
treatment of premature ovarian failure.  There are very few randomised trials, or even cohort 
studies, in this area.  It is important when interpreting the results to remember that the no 
treatment group was self-selected and actively chose to continue not to take treatment at each 
time-point.   
Comparison between the HRT and COCP groups revealed a significant difference in lumbar 
spine BMD at 24 months in favour of HRT (0.038 g/cm2; 95% CI 0.002 to 0.073; p 0.040), which 
was the primary outcome for this study.  However there were no significant differences between 
the HRT and COCP groups’ bone marker results.   
We found that women who chose not to take any hormonal treatment in POF were as expected 
actively losing bone.  This group experienced a drop in bone density at the lumbar spine, total 
hip and femoral neck.  Differences are highly significant between HRT and no treatment groups 
at the lumbar spine and between both COCP and HRT versus no treatment at the total hip.  
These findings were supported by results from bone marker analysis.   
HRT performed favourably compared with the COCP in lipid profile, sexual function, blood 
pressure and depression scores, although most differences were not statistically significant.  
Larger sample sizes are needed to confirm and quantify differences and results from this trial 
could be used to help calculate sample sizes for future trials.  HRT also appeared to provide a 
more rapid control of menopausal symptoms, with improvements from 3 rather than 6 months.   
In summary, it appears that HRT has a more favourable effect than COCP on bone density and 
several other parameters in POF.  However, it is also clear that choosing to take no treatment 
has a poor effect on bone health and symptoms and it is preferable to take any form of hormone 
treatment rather than none.  Some women will not find HRT an acceptable medication to take 
and it would be better for these women to take the COCP than nothing at all.   
It is also highly likely that different doses and routes of oestrogen replacement may have 
different effects on bone density and metabolism and this is an area that deserves further 
investigation.  There is currently one trial underway which is evaluating the effects of micronised 
progesterone and medroxyprogesterone acetate, both in conjunction with transdermal 
oestradiol, on the cardiovascular system, lipid profile and coagulation cascade (174).  There is a 
double-blind randomised controlled trial recruiting in America comparing DHEA versus placebo 
on pregnancy rates in POF (114).  However, given that bone health is a major concern for 
women with POF and the fact that osteoporosis and resultant fractures can have major 
implications in later life, further research needs to be carried out in this area.  Sexual function is 
also a concern in POF and in cross-sectional studies has been consistently found to be lower 




confirmed in larger studies and the role of testosterone replacement in spontaneous POF, as 





Chapter 7  Appendices 
7.1 Appendix A: Inclusion and Exclusion Criteria 
Inclusion criteria 
Age 18-44 years 
Women with a diagnosis of POF within the last 36 months (with documented FSH level >30IU 
on 2 occasions 4-8 weeks apart) 
Ability to understand English 
Written informed consent for participation in the trial 
 
Exclusion criteria 
Age less than 18 or over 44 years 
Current desire for pregnancy is an exclusion criterion from the active treatment group (as she 
may be randomised to take COCP).  However, she could elect to take part in the no treatment 
group.   
Women with absolute contraindications to hormone treatment will be excluded from the active 
treatment group (i.e. personal history of thromboembolic disease, oestrogen dependent 
malignancies, and personal history of focal migraine).   
Women taking medication for high cholesterol or found to have raised cholesterol levels 
requiring treatment on initial assessment.   






7.2 Appendix B: Modified Greene Climacteric Scale 
  
  
Modified Greene Climacteric Scale 
 
Please indicate the extent to which you are bothered at the moment by any of these 
symptoms by ringing the appropriate number. 
 












0      1      2      3 
 Feeling dizzy or 
faint 
 
0      1      2      3 




0      1      2      3 
 Pressure or 
tightness in head or 
body 
 
0      1      2      3 




0      1      2      3 
 Parts of body 
feeling numb or 
tingling 
 





0      1      2      3 
 Headaches  
0      1      2      3 




0      1      2      3 
 Muscle or joint 
pains 
 





0      1      2      3 
 Loss of feeling in 
hands or feet 
 
0      1      2      3 
Feeling tired or 
lacking in energy 
 
 




0      1      2      3 




0      1      2      3 
 Hot flushes  
0      1      2      3 




0      1      2      3 
 Sweating at night  





0      1      2      3 
 Loss of interest in 
sex 
 





0      1      2      3 






7.3 Appendix C: Menopause Symptoms-Treatment Satisfaction 
Questionnaire 
  
Menopause Symptoms Treatment Satisfaction Questionnaire 
We are interested in learning what you think about the pill you’ve been taking as a part of this 
study.  Please rate how satisfied you’ve been with each of the following during the past 4 
weeks by checking one box for each question. 
1. During the past 4 weeks, how satisfied have you been with the ability of the study 













2.  During the past 4 weeks, how satisfied have you been with the ability of the study medication to control your 













3.  During the past 4 weeks, how satisfied have you been with the effect of the study medication on the quality 













4. During the past 4 weeks, how satisfied have you been with the effect of the study 













5. During the past 4 weeks, how satisfied have you been with the effect of the study 



























7. While taking some medications, some people may experience side effects.  How satisfied have you been 






























7.4 Appendix D: Brief Profile of Female Sexual Function 
  
 Brief Profile of Female Sexual Function Questionnaire 
In this questionnaire you will be asked about your sexual feelings and activity.  Read each statement 
carefully and select the response that best corresponds to your experience over the past 2-3 months 
 
I felt like having sex 
Never                   Seldom                   Sometimes                   Often                   Very often                   Always 
 
I was unhappy about my lack of interest in sex 
Never                   Seldom                   Sometimes                   Often                   Very often                   Always 
 
Getting aroused took forever 
Never                   Seldom                   Sometimes                   Often                   Very often                   Always 
 
I felt sexually numb 
Never                   Seldom                   Sometimes                   Often                   Very often                   Always 
 
I lacked sexual desire 
Never                   Seldom                   Sometimes                   Often                   Very often                   Always 
 
I felt disappointed by my lack of interest in sex 
Never                   Seldom                   Sometimes                   Often                   Very often                   Always 
 
I reached orgasm easily 




















Patient Health Questionnaire – 9 
 
Over the last 2 weeks, how often have you been bothered by any of the following problems? 
 
1.  Little interest or pleasure in doing things 
Not at all  Several days  More than half the days  Nearly every day 
 
2.  Feeling down, depressed, or hopeless 
Not at all  Several days  More than half the days  Nearly every day 
 
3.  Trouble falling or staying asleep, or sleeping too much 
Not at all  Several days  More than half the days  Nearly every day 
 
4.  Feeling tired or having little energy 
Not at all  Several days  More than half the days  Nearly every day 
 
5.  Poor appetite or overeating 
Not at all  Several days  More than half the days  Nearly every day 
 
6.   Feeling bad about yourself – or that you are a failure or have let yourself or your family down 
Not at all  Several days  More than half the days  Nearly every day 
 
7.  Trouble concentrating on things, such as reading the newspaper or watching television 
Not at all  Several days  More than half the days  Nearly every day 
 
8.  Moving or speaking so slowly that other people could have noticed?  Or the opposite – being so 
fidgety or restless that you have been moving around a lot more than usual. 
Not at all  Several days  More than half the days  Nearly every day 
 
9.   Thoughts that you would be better off dead or hurting yourself in some way 
Not at all  Several days  More than half the days  Nearly every day 
 
 
If you checked off any problems, how difficult have these problems made it for you to do your work, take care 
of things at home, or get along with other people? 
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